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South Africa recently experienced a Listeriosis outbreak, which was responsible for over 180 
deaths, caused by an intracellular, rod-shaped bacilli called Listeria monocytogenes (LM). LM 
can infect both phagocytic and non-phagocytic cell types and induces its uptake by expressing 
internalin A and B, then secretes listeriolysin O (LLO), a virulence factor forming pores on the 
phagosome membrane to escape into the cytosol. Macrophages can phagocytose invading 
pathogens and induce innate inflammatory responses. Production of cytokines and eicosanoids 
by antigen presenting cells activates the adaptive immunity. Eicosanoids (epoxyeicosatreinoic 
acids, prostanoids and leukotrienes) are generated from metabolites of 20-carbon chained poly-
unsaturated fatty acids and arachidonic acid. Leukotrienes (LTs) are generated from 5-
lipoxygenase-metabolism of arachidonic acid to LTB4 and cysteinyl LTs (cysLTs). CysLTs are 
pro-inflammatory lipids that have pathobiological functions in asthma. CysLTs function 
through three G-protein coupled receptors (CysLTR1, CysLTR2 and GPR99). The CysLTR1 
and its ligands function has been well elucidated in asthmatic and allergic responses however, 
its role in bacterial infections is unknown. The aim of our study was to elucidate the role of 
CysLTR1 on disease progression in mice and macrophages infected with LM. In this study, we 
showed that CysLTR1 mRNA expression is upregulated by LM infection in WT macrophages 
and mice. Mice deficient of CysLTR1 had no defects at homeostasis. During time kinetic 
experiments with LM, CysLTR1 knockout mice displayed increased neutrophil recruitment and 
decreased lymphocyte cells at 3dpi, however, bacterial burdens were comparable to wild-type 
mice. In addition, macrophages deficient of CysLTR1 have no effect on the intracellular growth 
of LM. In conclusion, CysLTR1 signalling plays a role in lymphoid cell activation and 
neutrophilic recruitment during early LM infection, however, further studies are required to 
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CHAPTER 1: INTRODUCTION 
1. Listeria monocytogenes 
Listeria monocytogenes (L. monocytogenes or LM) was initially described as Bacterium 
monocytogenes by E.G.D. Murray in 1940, then later changed to the genus name Listeria 
in 1962 (1, 2). There are 17 Listeria genus species that have been recognized so far, namely; 
L. monocytogenes, L. seeligeri, L. ivanovii, L. welshimer, L. marthii, L. innocua, L. grayi, 
L. fleschmannii, L. floridensis, L. aquatica, L. newyorkensis, L. cornellensis, L. rocourtiae, 
L. weihenstephanensis, L. grandensis, L. riparia and L. booriae (3). L. monocytogenes and 
L. ivanovii are the two only species that are known to be pathogenic, with L. monocytogenes 
being an important human foodborne pathogen (4, 5). 
L. monocytogenes is a facultative intracellular Gram-positive bacterium that is the 
causative agent of Listeriosis (6). LM mostly causes infection in immunocompromised 
individuals, elderly people, pregnant women, and neonates (7–9). LM can be isolated from 
soil, plants and water, and can cause disease in both animals and humans (10, 11), and 
causes neonatal infection, sepsis and meningitis in immunocompromised individuals (12). 
In 2016, the centre for disease control (CDC) reported that listeriosis infects about 1600 
immuno-incompetent individuals, which include pregnant women and neonates in the 
United State, with an estimate of 260 deaths each year (7). Between 2017 and 2018, South 
Africa had an outbreak of Listeriosis, with 674 reported cases and 183 patient deaths due 
to the disease of which 42% were neonates infected during pregnancy or delivery (13).   
1.1. L. monocytogenes pathogenesis  
 L. monocytogenes is introduced into the human host through ingestion of contaminated 
foods. When the bacterium is ingested, it crosses the intestinal barrier through the blood 
and the lymphatic system to the liver and spleen. In the liver, the bacteria replicates in the 
hepatocytic macrophages and then spreads via blood to cross barriers such as brain and the 
placenta (14). Therefore, LM can infect macrophages and various other cell types and this 
ability is mostly facilitated by its virulence factors discussed below.  
1.2. Host cellular invasion by L. monocytogenes 
Invasion of the host cellular system by LM is initiated by two surface proteins, internalin 
A (InlA) and B (InlB). InlA interacts with epithelial cadherin (E-cadherin) expressed on 
epithelial cells, to induce LM uptake (15). While InlB induces LM uptake by various other 
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cells such as liver hepatocytes, tissue fibroblasts and epithelial cells by interacting with 
host tyrosine kinase, Met receptor (16–18). Therefore, InlA and InlB allow the 
internalization of LM by phagocytic and non-phagocytic cells, and it becomes entrapped in 
a vacuole.  
Once internalized in a vacuole, to promote its survival LM secretes a pore-forming toxin, 
Listeriolysin O (LLO) and two phospholipases (PlcA and PlcB) depending on the cell type, 
to disrupt the phagosome membrane and promote its escape into the host cytoplasm (19). 
LLO forms pores around the phagosome, while PlcA and PlcB cause damage that results 
in the lysis of the phagosome membrane (20). In the cytoplasm, LM replicates and becomes 
motile by exploiting host actin through the actin polymerization factor (ActA), which 
enables the bacteria to polymerize host actin to propel into neighbouring cells. During this 
cell-to-cell spread, LM trapped in a double membrane vacuole when propelling from the 
cytoplasm through membrane protrusions into nearby cells (19–24). This mode of 
dissemination renders this bacterium virtually invisible to immune system. The secondary 
double-membrane vacuole can also be lysed by LLO, PlcA and PlcB, leading to the re-
initiation of this infection cycle (19, 25). Through the expression of these virulence factors, 
LM is able to cross the intestinal barrier, and spreads through the bloodstream or lymph to 
the mesenteric lymph nodes, spleen and the liver and can cross the blood-brain barrier and 
fetoplacental barrier (24, 26).  
1.3. Host cellular immunity to L. monocytogenes infection 
During any pathogenic infection, the host must induce an appropriate immune response to 
clear the infection. The interaction between the innate and adaptive immunity is therefore 
is essential for the control of pathogenic infections. During LM infection, innate immunity 
is responsible for detecting and controlling the infection, and adaptive immunity clears and 
hence protection for future infections (27). The innate immune cells detect microbial and 
danger associated molecular patterns (MAMPs and DAMPs) through patter recognition 
receptors (PRRs) expressed on their cell surface and in endosomes (28). These innate 
immune cells include macrophages, neutrophils, dendritic cells (DCs), granulocytes and 
monocytes, and they are the first line of defence during intracellular bacterial infections. 
Although natural killer (NK) cells are lymphoid cells, they also play a role in innate 
immunity during tumour, viral and bacterial invasion. 
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LM expresses ligands that can be recognized by the toll-like receptor (TLR) 2 that 
recognizes bacterial peptidoglycan, lipotechoic acid and lipoproteins, TLR5 that 
recognizes LM flagellin, TLR9 which recognizes the CpG motif of the bacterium DNA, 
and nucleotide-binding oligomerization domain-containing protein 2 (NOD2), which 
recognizes muramyl dipeptide. Recognition of these MAMPs all result in the activation of 
the nuclear factor κB (NF-κB) which increases pro-inflammatory cytokine secretion (29–
32). It has been shown that mice lacking CCR2 (a chemokine receptor for MCP-1 and 
MCP-3), IFN- γ  and TNF receptor are susceptible to LM infection (33–35). These 
chemokines and cytokines are essential for the optimal innate immunity against LM 
infections, as they increase macrophage and neutrophil recruitment and enhance 
microbicidal functions to control bacterial burden before the onset of the adaptive 
immunity.  
The macrophages and DCs play a crucial role during LM infection, they can engulf the 
invading pathogens, resulting in the activation of the innate immunity. LM infected DCs 
result in the recruitment of granulocytes, NK cells and monocytes to the site of infection in 
response to IL-12 secretion (36). Recruitment of NK cells enhances the production of IFN- 
γ  required for further activation and maturation of DCs and macrophages (9, 36, 37). 
However, it has been also demonstrated that NK cell stimulation can be detrimental for the 
host during LM infection (38). LM secrets a protein and virulence factor, p60, which can 
indirectly stimulate NK cells (39). Activation and maturation of DCs is essential during 
infection, as it enhances surface co-stimulation receptors (CD80, CD86, CD70) and 
cytokines (IL-12p70, IL-18, IFN-α/β) (40). These DCs migrate to the infection-associated 
secondary lymphatics, where they interact with the naïve T cells in the draining lymph 
nodes (41). During LM infection DCs have been shown to be the source of IL-12 leading 
to resistance to infection through production of IFN- γ  (42–44). Subsequently, IL-12 drives 
the rapid recruitment of NK cells, granulocytes and monocytes during LM infection (36).  
Macrophages internalize the bacterium and it becomes entrapped in a vacuole or 
phagosome. As the phagosome matures, macrophages create a toxic environment for the 
bacterium to inhibit its escape into the cytosol. However, for an effective control of LM by 
macrophages, they must be activated. Activation of the macrophages infected with LM 
results in the generation of nitric oxide (NO) through hydrolysis of L-arginine by inducible 
nitric oxide synthase (iNOS) (45). Production of reactive oxygen and nitrogen species 
(ROS and RNS) by macrophages inhibits the escape of LM from the vacuole into the 
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cytosol (46). LM-infected macrophages secrete TNF, IL-12 and some chemokines (such as 
MIP2) which allow stimulation and recruitment of other immune cells. For instance, IL-12 
regulates the development of T cells that secrete IFN-γ, TNF, and IL-2. TNF and IL-12 
secretion by macrophages, increases the major histocompatibility complex class II 
(MHCII) and co-stimulatory molecule expression, enabling antigen presentation to T cells. 
This also leads to T cell and NK cell activation. IFN- γ secretion, together with TNF, result 
in complete activation of macrophages and LM killing through NO production (47–49). 
Macrophages also secrete IL-1, IL-6 and chemokines responsible for neutrophil 
recruitment and activation (50).  
Production of CXCL1 and CXCL2 during LM infection recruits neutrophils to the site of 
infection (51). Neutrophils phagocytize the LM to limit its spread, and these are ingested 
by macrophages which kill the bacteria. Their ability to kill LM is contributed to by their 
ability to produce reactive oxygen species and are important for bacterial killing (52). 
Another mechanism that neutrophils employ to inhibit LM spread is neutralizing its 
virulence factor LLO. It has been shown that during phagocytosis by neutrophils, the 
matrix metalloproteinase-8 (MMP), an endoprotease that degrades LLO thereby prevents 
the bacteria from perforating the infected neutrophil, therefore, entrapping it within the 
phagosome (53).  
T lymphocytes form a large component of the adaptive immunity and is essential for the 
clearance of LM and to generate memory for future infections. LM infected antigen 
presenting cells (APCs) present a peptide fragment of the antigen to T cells through major 
histocompatibility complex I (MHC-I) and II (MHC-II) (48). LM antigen presented by 
MHC-I by DCs/macrophages to CD8 T cells to mounts a protective cytotoxic T 
lymphocyte (CTL) response against LM infection (54). CD8 T cells induce immunity to 
LM by either lysing the infected cells via perforin and granzymes, or by secreting IFN-γ 
that in turn activates macrophages for an effective killing of the bacterium (55). It has been 
demonstrated that mice primed with killed LM generate long-term CD8 T cell mediated 
immune response to LM infection (56). Upon re-infection, CD8 memory T cells induce a 
rapid elimination of infected cells by invading pathogens to provide protective immunity 
(57). The memory CD8 T cells are recruited to the site of infection, where they secrete 
IFN-γ for macrophage activation and rapidly secrete granzyme and perforin directed to 
infected cells (58). In response to LM infection, IL-12 and type 1 interferons have been 
shown to induce CD8 T cell memory development (59). APCs can, however, present LM 
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antigens to CD4 T cells via the MHC-II resulting in IFN-γ secretion to further activate 
macrophages (60). CD4 T cells help memory CD8 T cell expansion after re-infection with 
the same pathogen (61) and arerequired for the long-term maintenance of memory CD8+ T 
cells and function by maintaining their ability to respond to IL-7 and IL-15 (62). More 
recently, it has been shown that LLO specific CD4 T cells transition into long-term memory 
populations that resemble their parent effector T cells. These effector and memory T cells 
predominantly have a Th1 profile that result in production of IFN-γ, TNF, and IL-2 and 
minimal production of IL-17A. Deletion of CD4 T cells during LM infection results in 
increased bacterial burden, proving that memory CD4 T cells might play a crucial role in 
intestinal intracellular bacteria (63). Therefore, both CD4 and CD8 memory T lymphocytes 
play a role in the clearance and control of LM infection during secondary infection.  
Antibodies have been shown to play a minor role during LM infection. Antibodies reduce 
early dissemination of LM to vital organs by trapping the bacteria and their antigens in 
secondary lymphoid organs where specific immune responses are initiated. B cells and 
antibodies can also facilitate the generation of the protective T cells responses (64). They 
have also been shown to play a role in generation of memory CD8 T cells during LM 
infection (65).  
2. What are Eicosanoids? 
Eicosanoids are a lipid mediator family of enzymatically generated metabolites of 20-
carbon polyunsaturated fatty acids (PUFAs) (66, 67). Eicosanoid biosynthesis begins with 
the release of arachidonic acid (AA), esterified in the sn-2 domain of membrane 
phospholipids, by the action of phospholipase A2 (PLA2), particularly group IVA cytosolic 
cPLA2 (68). Eicosanoids are synthesized primarily by three enzymatic oxygenation 
pathways, each involving a distinct family of enzymes; cyclooxygenases (COXs), 
epoxygenases, and lipoxygenases (LOs) (66). The enzymatic activities of prostaglandin 
G/H synthases or COXs, lipoxygenases, and epoxygenases respectively result in the 
formation of prostaglandins (PGs) and thromboxanes, leukotrienes, and 





Figure 1: Eicosanoid synthesis and signalling receptors.  Eicosanoid biosynthesis results from 
the esterification of the phospholipase A2 (PLA2), leading to the activation of the arachidonic acid 
(AA) pathway. The three enzymatic pathways involved in the synthesis of eicosanoids include 
cyclooxygenases (COX1/2), epoxygenases (also known as cytochrome P450, CYP) and 
lipoxygenases (LOX) (69). 
Eicosanoids play an important role in the function of immune cells. Receptors for 
eicosanoids are widely expressed throughout the immune system and function at multiple 
levels in both innate and adaptive immunity. The immunoregulatory properties of 
eicosanoids and their receptors result from their ability to modulate the production of 
cytokines and the expression of cytokine receptors, cell surface molecules in both an 
autocrine and paracrine manner. They therefore provide a link between innate and adaptive 
immunity (70).  
Prostaglandins and thromboxanes are collectively termed the prostanoids, which are widely 
generated in response to diverse stimuli and act in a paracrine or autocrine manner, while 
playing important roles in normal physiology and in diseases (68). Epoxyeicosatrienoic 
acids are autocrine and paracrine effectors in the cardiovascular system and kidneys. They 
regulate the transportation of ion and gene expression, while initiating vasodilation and 
have anti-inflammatory and pro-fibrinolytic effects (71). Leukotrienes induce acute 
inflammatory responses such as increased vascular permeability and recruitment of 
granulocytes, while prostaglandins also have pro-inflammatory effects by increasing 
vascular permeability but also exert immune-suppressive effects (72).   
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3. Synthesis of Leukotrienes 
Leukotrienes (LTs) are a group of eicosanoids generated from the 5-lipoxygenase-(5-LO-
) metabolism of AA to form leukotriene B4 (LTB4) and the cysteinyl LTs (CysLTs), LTC4, 
LTD4 and LTE4 (73). LTs are lipid mediators that have potent proinflammatory activities 
(74, 75). LTs are predominately synthesized by inflammatory cells such as leukocytes, 
macrophages, and mast cells. The cellular activation by immune complexes, bacterial 
peptides, and other stimuli elicit a sequence of events that induce cPLA2 and 5-LO 
translocation to the nuclear envelope (76). The activation of both the cPLA2 and 5-LO 
enzymes involves increased intracellular calcium levels and enhances the activation of 
protein kinase C (PKC). The AA is converted to 5-hydroperoxy-eicosatetraenoic acid (5-
HPETE) and subsequently to an unstable intermediate, LTA4, by the enzyme 5-LO (Figure 
2) (77). 5-LO is required to be translocated from the cytosolic or nucleoplasmic 
compartment to the perinuclear envelope, where it acts in concert with 5-LO activating 
protein (FLAP), which is required for 5-LO to function enzymatically in intact cells (78).  
LTA4 is preferentially hydrolysed to the dihydroxy leukotrienes, LTB4, by LTA4 hydrolase 
in the neutrophils (79). However, in eosinophils, basophils, mast cells and macrophages, 
through conjugation of LTA4 to a reduced glutathione by LTC4 synthase (LTC4S) forms 
LTC4. LTC4S is the terminal enzyme involved in the cysteinyl leukotriene (Cys-LT) 
synthesis (80–82). The formed LTC4 is exposed to the cell surface through a specific 
energy dependent step. It is converted extra-cellularly to LTD4 by a γ-glutamyl 
transpeptidase (γ-GT) or by a more functionally specific enzyme, γ-glutamyl leukotrienase 
(γ-GL) (83). LTD4 is then converted to LTE4 by a dipeptidase (84). LTE4 is excreted in the 
urine without undergoing any chemical modification (85).  
All the leukotrienes synthesised by the enzyme LTC4S (LTC4, LTD4 and LTE4), are 
collectively termed cysteinyl leukotrienes (CysLTs) since they are peptide-conjugated 
lipids. Leukotrienes were initially identified by their contractile properties on intestinal and 
bronchial smooth muscle (86, 87). However, they are now better recognised as potent 





Figure 2: Biosynthesis of leukotrienes. Stimuli presented by the cellular membrane result in the 
deoxygenation of the arachidonic acid released by the cytosolic phospholipase A2alpha (cPLA2alpha) 
from phospholipids, resulting in the formation of 5-HPETE and leukotriene A4 (LTA4). LTA4 is 
further hydrolysed to leukotriene B4 (LTB4) by LTA4 hydrolase or synthesized by leukotriene C4 
synthase to cysteinyl leukotrienes C4, D4, and E4 (LTC4, LTD4 and LTE4) (89).  
 
3.1. Cysteinyl leukotriene receptors and their functions 
Once the CysLTs have been synthesized, they bind to specific receptors to exert their 
biological functions. CysLTs exhibit several biological functions through two specific G 
protein-coupled receptor (GPCR) subtypes termed cysteinyl leukotriene type 1 receptor 
(CysLTR1) and CysLT type 2 receptor (CysLTR2) (78). CysLTR1 binds LTD4 with a 
higher affinity than LTC4, whereas CysLTR2 binds both LTC4 and LTD4 with equal 
affinity (88). Another CysLT receptor, GPR99 has been recently identified to preferentially 
bind LTE4 (90). 
CysLTR1 and CysLTR2 signalling is mediated through intracellular mobilization of 
calcium (91). CysLTR2 is about 38% identical to CysLTR1 and are both expressed in the 
same tissues such as smooth muscle and substantially in myeloid cells. There is an partial 
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overlap of the two receptors, which suggest that they may have complementary and distinct 
functions (83). It has been shown that IL-4 significantly induces the expression of 
CysLTR1 and CysLTR2 at a protein and RNA level in monocytes and eosinophils. 
However, CysLTR2 expression is also induced in T cells and  B cells when stimulated with 
IFN-γ (92). It has also been suggested that IL-4 and IL-13 can modulate CysLTR1 
expression in human monocytes and macrophages, and their responsiveness to LTD4 (93). 
There is very limited data describing the function of GPR99 or CysLTR3, however has 
been recently shown that during aeroallergen inhalation it regulates airway brush cells 
expansion and function through binding to the ligand, LTE4 (94). 
Besides their function on immune regulation, CysLT receptors have been suggested to have 
a functional role in signalling pathways. Once CysLTs bind to their specific CysLT 
receptors, they activate a cascade of downstream signalling pathways. Activation of 
CysLTR1 induces PI3K-Akt signalling, which leads to the nuclear translocation of B-
catenin (β-cat) and the activation of target genes that include cyclin D1, COX-2 and c-Myc 
(Figure 3) (95). Akt/PKB activation leads to the activation of the IκB kinase (IKK) complex 
resulting to the subsequent degradation of IκB protein leading the translocation and 
activation of nuclear factor κB (NF-kB) (96). The signalling of CysLTR1 and CysLTR2 
can activate the phospholipase C (PLC) and Ras-Raf-MEK-ERK pathways (95, 97, 98). 
This cascade of events results in the translocation of Erk 1/2 leading to the activation of 
genes that play a role in proliferation, migration and survival. Ligation of the CysLT 
receptors can alternatively activate the PKC pathway and the transcription factor cAMP 
response element-binding protein (CREB) (95). 
Though the CysLT receptors may play a role in the activation and regulation of distinct 
signalling pathways, there is also a cross-regulation that occur between these receptors. 
Binding of LTC4 or LTD4 to CysLTR2 negatively regulates the signalling of CysLTR1 
through the receptor heterodimerization. A newly identified CysLT receptor, GPR17, has 





Figure 3: CysLTR1 cellular signalling pathways. Activation of cysLTR1 through binding of 
LTD4 leads to the activation of PI3K resulting in β-cat membrane translocation and cyclin D1, 
COX-2 and c-Myc activation. Binding of LTD4 to CysLTR1 may also induce membrane ruffles 
through P13K signalling. CysLTR1-LTD4 signalling activates the PLC pathway with a subsequent 
induction of MEK1/2, and alternately activates PKC and the transcriptional factor CREB resulting 
to cell proliferation, migration and survival (95).  
 
4. Eicosanoids role in inflammation and related diseases 
Eicosanoids do not only have a role in inflammatory diseases, but leukotrienes, particularly 
cysLTs, have been shown to play a significant role during brain injuries and in cognitive 
functions. Farias et al.(100), co-cultured blood neutrophils with rat neurons, glia cells and 
stimulated them with calcium and they detected high levels of LTC4, LTD4 and LTE4. This 
suggested that glia cells and neurons participate in a transcellular biosynthesis of 
leukotrienes. They hypothesized that the LTC4 formation may be unveiled in the genesis 
and progression of inflammatory responses as a result of brain injury (100). In 2009, using 
fluid percussion injury to model traumatic brain injuries, they showed that cysLTs are 
upregulated within an hour after the injury. The increased production of cysLTs was 
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contributed by neutrophils through a transcellular biosynthesis mechanism. They further 
demonstrated that treating the rats with MK-886 (FLAP antagonist), resulted in decreased 
cysLT synthesis, which correlated with a reduction in brain lesions (101). The same 
research group conducted another study demonstrating that leukotriene synthesis plays a 
role in the pathophysiology of traumatic brain injury (102). In a healthy brain, leukotrienes 
cannot be detected, however in a mechanism that involves neutrophils and brain cells, 
leukotrienes are rapidly synthesized in the brain after a traumatic injury (101, 103). By 
blocking leukotriene synthesis using MK-885, the researchers demonstrated that rats 
treated with FLAP inhibitor before or after brain injury had decreased leukotriene 
production, brain edema, attenuated brain-blood barrier disruption and deficits. MK-886 
treatment also improved post-injury spatial learning and the memory of the rats (102). 
These results indicate that leukotrienes are not only released during brain injury, but they 
also affect cognitive functions, and targeting their production reverses their effect on brain 
and cognitive deficits.  
Lai et al. 2014, conducted a study to investigate the effect of montelukast targeting 
CysLTR1 on spatial learning and memory in bilateral intracerebroventricular infusions of 
Aβ1-42-injected mice. Aβ1-42 is used as experimental model for Alzheimer’s disease (AD) 
for testing learning and memory. They found that mice injected with Aβ1-42 had learning 
and memory deficits which were accompanied by increased inflammatory and apoptotic 
responses, supported by the NF-κβ p65, TNF-α and IL-1β increase, caspase-3 activation 
and decreased Bcl-2 in the hippocampus and cortex. The Aβ1-42 injection also increased 
CysLTR1 expression in both these regions of the brain. The effects of Aβ1-42 were 
reversed when mice were treated with montelukast. Their results suggested that the 
reversed Aβ1-42-induced cognitive defects by montelukast is partially contributed by 
inhibition of neuronal inflammation and apoptosis which is mediated by CysLTR1 
signalling (104). 
4.1. CysLTR1 in asthma and other inflammatory diseases 
Eicosanoids (leukotrienes and prostaglandins) have been well elucidated in asthmatic 
inflammation. They have also been shown to play a role in aspirin-exacerbated respiratory 
disease (AERD). In a study by Mastalerz et al. 2014 (105), to investigate whether inhaled 
lysyl-aspirin on sputum supernatant induces eicosanoid production during bronchial 
challenge test. They compared asthmatic patients with hypersensitivity to nonsteroidal anti-
inflammatory drugs with asthmatic patients that are aspirin tolerant. AERD patients had 
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significantly higher LTD4, LTE4, PGD2. After challenging the patients with lysyl-aspirin, 
there was an increase in LTD4 and LTE4, while PGE2 and LTB4 decreased in AERD 
subjects (105). 
A study conducted by Zhu et al. (106),  aimed to identify whether the leukotriene receptor 
antagonist (LTRA) targets are present in the bronchial mucosa and if they are upregulated 
in asthma patients. LTRA is a type of medication or antagonist which works as leukotriene-
related enzyme inhibitor or leukotriene receptor antagonist, opposing the function of the 
leukotriene mediators. These LTRAs include CysLTR1 antagonists (montelukast, 
zafirlukast, and pranlukast) and 5-LO antagonists (zileuton and Hypericum perforatum), 
and are used in asthma treatment (107, 108). They demonstrated bronchial mucosal 
eosinophils, neutrophils, mast cells, macrophages, B lymphocytes and plasma cells 
expressed CysLTR1, but T lymphocytes did not. They also showed that the inflammatory 
cells in patients with stable and exacerbated asthma was greater than in non-smoking and 
nonatopic control subjects. This study demonstrated that the LTRA targets are present in 
the bronchial mucosa and are upregulated during asthma and exacerbated asthma (106).  
Bouduad et al. 2018, conducted a study to investigate whether IL-33 is able to regulate 
cysLT receptor expression (109). It has been demonstrated that IL-33 plays a role in the 
initiation of immune responses during an asthmatic reaction (110–113). As mentioned, 
cysLTs have been well studied in asthmatic responses and it has also been shown that 
CysLTR1 is highly upregulated during asthma in leukocytes (106) however, the interaction 
between IL-33 and CysLTR1 was not fully understood. Boudaud et al., showed that IL-33 
in human peripheral blood lymphocytes (PBLs) upregulated the expression of CysLTR1 at 
protein but not at mRNA level. The increased CysLTR1 protein expression was consistent 
with how these cells responded to LTD4 through calcium mobilization and CD4 T cell 
migration. CysLTR1 expression was also increased in naïve and memory CD4 T cells in 
response to IL-33, opposing what was shown by Zhu et al., 2005 (106). This response was 
independent of APCs (109),  and could be a therapeutic target for treatment of asthma. 
CysLTR1 expression is not only induced by its binding ligands, various studies have 
demonstrated that CysLTR1 expression can be regulated by certain cytokines besides IL-
33. For instance, CysLTR1 is upregulated by IL-13 and IL-4 in human monocytes and 
macrophages (114),  IL-5 in eosinophils differentiated from HL-60 cells (115), TGF-β and 
IL-13 in bronchial smooth muscles (116) and IFN-γ in human airway monocytes and 
peripheral cells (117, 118). In 2015, Thivierge et al. (119), demonstrated that T cell 
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expression of CyLTR1 is elevated by allergen in  a mechanism that involves secretion of 
IL-4, in turn, this would promote the response of CD4 T cells to cysLTs and Th2 immune 
activation (119). However, besides IFN-γ being proven to enhance the expression of 
CysLTR1 in some immune cells, it has not been demonstrated whether it can upregulate 
CysLTR1 in Th1 cells. Although CysLTR1 and its ligands induce a robust Th2 immune 
response, it would be essential to therefore, demonstrate whether they play a role in Th1 
cell activation.  
4.2. Role of eicosanoids in microbial infections 
The function of PGE2 has been studied in a handful of microbial infections. During acute 
mucosal infection with Toxoplasma gondii in mice, it has been demonstrated that 
production of PGE2 is associated with inflammatory monocytes. Neutrophil activation was 
inhibited by these monocytes in a PGE2-dependent manner. Inhibition of PGE2 by 
indomethacin or celecoxib increased the activation of neutrophils and led to host mortality 
post T. gondii infection. These results therefore, suggest that PGE2 interaction with 
inflammatory monocytes is required for the modulation of the neutrophil mediated 
pathology during pathogen-induced inflammation  (120).  
It has also been reported that treatment of alveolar macrophages with PGE2 during 
Klebsiella pneumoniae inhibited their killing ability, and this effect was reversed by 
addition of adenylyl cyclase antagonist, which mimicked the actions of EP2 and EP4 
receptor inhibitors. Through EP2/EP4 receptors, PGE2 suppresses the microbicidal action 
of alveolar macrophages, which is associated by reactive oxygen intermediates (ROI) 
generation, activation of cAMP, protein kinase A, and blocking of NADPH oxidase 
phosphorylation and translocation to the phagosome membrane (121). This indicates that 
PGE2 suppresses the killing effect of macrophages by inhibiting the phagocytic activity in 
Klebsiella pneumoniae infections. During K. pneumoniae infection in LT deficient mice 
were more susceptible to infection compared to wildtype mice however, there were no 
defects in the recruitment of neutrophils to the lung. However; it was observed that 
bacterial phagocytosis and clearance were impaired in alveolar macrophages of the 
deficient mice. This defect was reversed by addition of LTB4 in vitro, suggesting that LTs 
have a significant role during bacterial pneumonia in mice model (122).  
Cyclooxygenase 2 (COX2), the enzyme responsible for PGE2 synthesis, has also shown to 
play a role during bacterial infection. Moreno et al., showed that during Mycobacteria 
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tuberculosis (Mtb) time course infection in mice, PGE2 expression is upregulated in a time-
dependent manner. They also observed that when prostaglandin production is suppressed 
during TB infection, there were differences in the pathology and immune response at early 
and late phase of infection. Blocking COX2 during early Mtb infection increased TNF-α 
and IFN-γ expression while it decreased IL-1α and iNOS expression. However, during the 
chronic phase of infection, IL-1α, TNF-α, IFN-γ and iNOS expression were increased, 
whilst the IL-4 and IL-10 expression was suppressed (123). These results suggest that 
inhibition of prostaglandin production by COX, particularly PGE2, has a significant role in 
the protection and disease progression during TB infection in mice.  
Leukotrienes have also been shown to play a role on other bacterial infections. For instance, 
infection of murine mast cells with Escherichia coli (E. coli), increased significant amounts 
of LTB4 and LTC4. Moreover, using mast cell deficient mice, it was observed that 
leukotrienes are responsible for the recruitment of neutrophils to the site of infection and 
subsequently resulting in bacterial clearance (124).  
More recently, it has been observed that Brucella abortus (B. abortus) upregulates the 
expression of 5-LO during infection in mice, upregulating the production of LTB4 and 
lipoxin A4 (also a product of lipoxygenase). When comparing wildtype to 5-LO deficient 
mice, liver and spleen bacterial burden were decreased with reduced liver pathology. This 
was accompanied by increased production of IL-12, IFN-γ and iNOS during time course 
infection (125). This demonstrated that 5-LO plays a role in host susceptibility during B. 
abortus infection by suppressing the host protective Th1 immune response.  
5. Role of Eicosanoids during Listeria monocytogenes infection 
Hutchison et al., 1987, investigated whether the suppression of LM phagocytosis by 
macrophages was due to the low-molecular weight component (prostaglandin) in spleen 
culture supernatants. This study demonstrated that PGE2 treated peritoneal macrophages 
able to supress phagocytosis of LM and addition of PGE2 inhibitor, indomethacin, 
compelety abrogated the inhibitory effect on the phagocytosis. These results suggested that 
prostaglandins, especially PGE2, are modulators of LM phagocytosis by macrophages 
(126). 
In 2008, Noor et al., conducted a study where they investigated the regulation of AA release 
and production of eicosanoid by resident macrophages during bacterial infection. Their 
study elaborated that LM infection activated cPLA2α in resident peritoneal macrophages, 
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which resulted in the release of AA and production of eicosanoids, particularly LTC4 and 
PGE2. Furthermore, the activation of cPLA2α involved the virulence factor, LLO, and the 
host toll-like receptor 2 (TLR2). This study also demonstrated that cPLA2α activation has 
an important role in the suppression of TNF production by LM-infected macrophages, 
suggesting that eicosanoids play a role in regulating immune responses during Listeria 
infection (127).  
More recently, Pitts et al., 2019, demonstrated that PGE2 inhibit neutrophil-mediated 
clearance of LM (128). PGE2 has been shown to inhibit reactive oxygen species (ROS), IL-
12 and TNF production (120, 121, 129). Pitts et al., hypothesized that increased PGE2 
production in BALB/cByJ mice microenvironment will inhibit liver ability to kill LM, 
which will contribute to susceptibility of the mice. PMN cells harvested from BALB/cByJ 
or C57BL/6J mice had decreased ability to kill LM after pre-treatment with PGE2 in vitro. 
Treatment with PGE2 slowed PMN migration to the chemoattractant to LTB4, decreased 
PMN uptake of LM, and respiratory rupture by PMN was inhibited compared to cells that 
were not treated. Their results demonstrated that secretion of PGE2 can inhibit the effector 
functions of neutrophils, resulting in reduced bacterial (LM) killing (128).   
Eicosanoids, particularly prostaglandins, have been shown to regulate immune responses 
to LM infection. This could be contributed by the modulation of the phagocytic effects of 
macrophages during bacterial infection, suppression of chemokine production and 
regulation of TNF, IL-6 and IL-10 levels (130–132). However, the effect of cysteinyl 
leukotrienes on LM infection has not been elucidated. The role of CysLTR1 has been well 
elucidated in the etiology of airway inflammation and asthma (133). However, the function 
of the receptor and its associated ligands in bacterial infection is still unknown. Therefore, 
we aim to elucidate the role of CysLTR1 in disease progression in mice and macrophages 
infected with Listeria monocytogenes. 
6. Rationale of the study 
As mentioned, Listeria monocytogenes (LM) is a facultative intracellular Gram-positive 
bacterium that is the causative agent of Listeriosis (6). Macrophages and dendritic cells can 
phagocytose an invading microorganism and induce an innate inflammatory response. 
However, the DCs play a central role in the transition between the innate and the adaptive 
immunity (70). The production of eicosanoids is an early response to microbial infection 
that can regulate the innate immune response (134). LM stimulates the release of the 
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arachidonic acid and eicosanoid production by peritoneal macrophages and the activation 
of group IVA cytosolic phospholipase A2. Increased production of endogenous mediators 
such as cytokines and eicosanoids can activate APCs, particularly DCs, which in turn 
activate the adaptive immune response (70).  
As mention above, South Africa recently experienced a Listeriosis outbreak which resulted 
in 674 reported cases, with 42% neonates cases (13). In 2015, South Africa was ranked 
amongst the highest fertility rates in African countries (135), with an estimate of infant 
mortality rate in 2017 being 32.8 per 1000 live births (136). Furthermore, Africa continent 
has the highest prevalence HIV, with approximately 12,6% of South African living with 
HIV and women are mostly infected (136). It is well known that Listeriosis mostly affects 
immunocompromised individuals, therefore, HIV infected patients are at higher risk of LM 
infection. 
Diagnosis of Listeriosis is difficult and can result in delayed treatment. This is because, 
Listeriosis can only be diagnosed by culturing LM bacterium from the patient’s blood, 
cerebrospinal fluid or amniotic fluid, on a medium that is selective for this bacterium with 
no serological tests available for diagnosis of Listeria. Treatment of Listeriosis includes 
intravenous (IV) antibiotic administration to prevent, stop or slow down progression of 
severe disease. The two antibiotics used to treat this disease are IV ampicillin and Bactrim, 
however, it has been advised that patient treatment should be individualized for optimal 
outcomes (13).  
The South African Listeriosis outbreak increased infant mortality, the chances of death 
among pregnant women, spontaneous abortions and neonate deaths in South Africa. The 
increased morbidity and mortality could be mostly contributed by the lack of rapid 
diagnostic tools for LM and delayed treatment. Therefore, a need for development for new 
interventions to diagnose, treat Listeria monocytogenes infections and to better understand 
the disease pathogenesis. Hence, this study is aimed at investigating host responses to LM 
infection, specifically a pro-inflammatory lipid modulator signalling pathway, namely 
cysteinyl leukotriene signalling. We aim to delineate the role of cysteinyl leukotrienes in 
pathogenesis of listeriosis by using cysteinyl leukotriene receptor knockout mice as a tool. 
We conducted a pilot mortality study where CysLTR1-/- (KO) and CysLTR1+/+ (WT) mice 
were infected with LM. Here, the CysLTR1-deficient mice presented with increased 
survival compared to wildtype mice during infection (Figure 4A). Furthermore, primary 
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bone-marrow derived macrophages were infected with LM, the gene expression of 
CysLTR1 and LTC4S (the enzymes responsible for cysteinyl leukotriene synthesis) were 
both upregulated early after infection at one- and three-hours however transient as it 
decreased at six hours post-infection (Figure 4B & 4C). This suggests that the Cysteinyl 
leukotriene pathway might play a role in disease progression and/or control during LM 
infection. We therefore hypothesize that CysLTR1 deletion in mice will result in a host 
protective phenotype during LM infection.  
 
Figure 4: Mouse survival and CysLTR1 and LTC4S expression following L. monocytogenes 
infection. A) CysLTR1-/- and CysLTR1+/+ mice (C57BL/6) were infected with 1x106 CFUs of LM 
and monitored over 15 days post-infection for survival, Statistically analysed by log-rank (Mantel-
Cox) test B-C) C57BL/6 wildtype mouse bone marrow derived macrophages (BMDMs) were 
infected with MOI of 10 to determine the gene expression of CysLTR1 and LTC4S using 
quantitative PCR. Error bar denotes mean ± SEM and analysed using the One-way ANOVA 
multiple comparison test (p < 0.05 *, p < 0.01**, p < 0.001***).  
 
6.3.Aim and Objective 
6.3.1. Aim of the study  
We aim to understand the role of cysteinyl leukotriene signalling on disease progression 
during Listeria monocytogenes infection 
6.3.2.  Objectives 
1. Measure the RNA expression levels of CysLTR1 in mice and macrophages by time 
course infection of wildtype mice and bone marrow-derived macrophages with LM 
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2. Characterization of CysLTR1-deficient mice and their littermate wild-type controls 
at naïve state  
3. Determine the effect of CysLTR1 deletion on macrophage ability to control LM 
infection  
4. Mortality and time kinetic studies to evaluate the effect CysLTR1 deletion during 




CHAPTER 2: MATERIALS AND METHODS 
1. Ethics statement 
This study was performed under the strict guidelines of the South African National 
Standard for the Care and Use of Animals for Scientific Purposes (SANS 10386:2008). All 
mouse experiments conducted according to the protocol approved by the Animal Ethics 
Committee of the Faculty of Health Science, UCT (Protocol number: AEC 019/031). Mice 
were euthanised by halothane inhalation and death confirmed by cervical dislocation at the 
humane endpoint or terminating the experiment.  
2. Mouse strains 
CysLTR1 deficient mice (Cysltr1-/-) were generated by breeding heterozygous (Cysltr1-/+) 
female and male mice. CysLTR1 heterozygous (Cysltr1-/+) mice were gifted by Dr 
Yoshihide Kanaoka of the Department of Medicine, Harvard Medical School (137). All 
mice were kept in ventilated cages under specific-pathogen-free condition in the 
biomedical animal facility of the UCT Faculty of Health Science. Mice were between 8-12 
weeks of age and sex matched for each experiment, unless stated otherwise.  
3. Mouse genotyping 
DNA extraction from mice tails: DNA from mice tails was extracted by incubating tails 
overnight in lysis buffer at 56oC overnight rotation and then centrifuged at 10000 rpm for 
10 to 12 minutes. Supernatants were collected and added to isopropanol tubes, gently 
mixed by inverting the tubes. The tubes were then centrifuged for 6 minutes at 10000 rpm, 
the supernatants were removed without disturbing the DNA pellets. 70% cold ethanol and 
incubated for 10 minutes. To get rid of the excess ethanol, the tubes were centrifuged at 
10000 rpm for 2 minutes and allowed to air dry. 500µl PCR water was added and the tubes 
were incubated for 20 minutes on a heating block to resuspend the DNA. 
Genotyping by PCR: To determine the mice genotypes, DNA from mice tails was 
genotyped by PCR using the following reaction mix: the DNA sample was mixed with 10X 
buffer, 10mM dNTPs, 25mM MgCl2, 5U/µL supertherm Taq, H2O and 6.25µM wildtype 
or knockout primers. The PCR reaction was ran under the following conditions 94oC 
denaturation for 2 minutes, 35 cycles of amplification (94oC for 20 seconds, 58oC for 30 
seconds and 72oC for 45 seconds), and extended annealing for 5 minutes at 72oC. CysLTR1 
deletion specific primers (5’-ATCTTGTTCAATGGCCGATCCCAT-3’ and 5’-




AATCATGTATACTTGGAAGGCTGA-3’) were used to confirm CysLTR1 deletion.   
4. Bacterial culture 
L. monocytogenes (virulent EGD strain) was cultured in Tryptic-Soy Broth (TSB) at 37oC 
with overnight shaking at 170 rpm. Overnight culture was sub-cultured in fresh TSB media 
and grown to mid-log phase (OD reading of 0.6 to 0.8) at 37oC. The bacterial culture was 
preserved in 20% glycerol and stored in -80oC until use. The stock concentration bacteria 
were determined by plating random vails. The dose was determined by plating inoculum 
before and after performing infection. 
5. Infection of mice with L. monocytogenes and determination of bacterial loads 
Mortality studies: CysLTR1-/- and CysLTR1+/+ mice on C57BL/6 background (10 per 
group, sex-matched and 8-12 weeks old) were infected with about 1x106 CFUs/200µL 
intraperitoneally and monitored for 15 days to compare the survival rate between the two 
groups. While CysLTR1-/- and CysLTR1+/+ mice on BALB/c background were infected 
with about 2x105 CFUs/200µL intraperitoneally. When mice showed weight loss of 20% 
to their initial body weight and/or show signs of severe sickness (lack of grooming, 
hunched back, pale extremities) the mice were euthanized, and death confirmed by cervical 
dislocation.  
Time-course studies: CysLTR1-/- and CysLTR1+/+ mice on C57BL/6 background (5-6 mice 
per group) were infected with about 5x105 CFUs/200µL L. monocytogenes 
intraperitoneally and sacrificed 3 days and 7 days post infection (dpi). Bacterial burden in 
the liver and spleen of LM infected mice were determined at 3- and 7dpi. The organs from 
euthanized mice were aseptically removed, weighed and homogenized in 0.1% Tween-80 
in saline. Neat, 101, 102 and 103-fold dilutions were plated on Tryptic-soy agar (TSA) plates 
and incubated at 37oC for 24 hours to determine the bacterial burdens. 
6. Histopathology of the liver, spleen and lung sections 
Portions of the spleen, liver and lung from naïve mice were fixed in 10% neutral buffered 
formalin (NBF, 3.8-4% formaldehyde, 4 g/L NaH2PO4, 6.5 g/L Na2HPO4, pH 7.0)  and cut 
into 3 sections (30-45 µm apart) and stained with haematoxylin and eosin (H&E) to 
determine any differences at naïve state. L. monocytogenes-infected liver and spleen tissue 
were fixed in 10 % NBF, cut into 3 sections (30-45 µm apart) and stained with H&E for 
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histopathology. Image acquisition and quantification was performed on Nikon 90i 
microscopy using NIS advanced software. 
7. Cytokine responses in organs at naïve state and post L. monocytogenes 
infection 
Homogenates of the lungs, liver and spleen of each mice were centrifuged at 3000 rpm for 
5 minutes. The supernatants were collected and the levels of IL-17, IL-10, TNF 
(BioLegend);  IFN-β, IFN-γ, IL-4, IL-6, IL-12p40, IL-12p70, IL-2, GM-CSF, IL-5, MCP-
1/CCL2, TGF-β (BD Biosciences); IL-1α, IL-1β, CCL5/RANTES, CXCL-10/IP-10 (R&D 
Systems) were all measured by ELISA according to manufacturers’ instructions and nitric 
oxide production using Griess reagent (138).  
. 
8. Immune cell populations in tissues at naïve and LM-infected mice by flow 
cytometry 
Single cell suspensions for the lung were obtained by digesting it in digestion buffer, 
DMEM containing 0.18 mg/ml Collagenase Type 1 (Sigma Aldrich) and 0.002 mg/ml 
DNAse I (Sigma Aldrich). The samples were rotated for 1 hour at 37oC, cells passed 
through 100 and 70 µm sieve in tandem, then centrifuges cells at 1200 rpm for 10 minutes 
at 4oC. The samples were then incubated with red blood cell (RBC) lysis buffer (155 mM 
NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) to remove contaminating erythrocytes. The cells 
were resuspended in complete media (DMEM + 10% FCS+ penicillin/streptomycin) and 
counted by Trypan Blue exclusion assay to determine the total number of live cells.  
Liver single cell suspensions were obtained by digesting in digestion buffer (DMEM + 
5%FCS containing 0.11 mg/ml Collagenase type I and 0.11 mg/ml Collagenase type II and 
0.001 mg/ml DNAse I) and incubated at 37oC for 30 minutes. The cells were passed 
through 100 and 70 µm cell strainer in tandem and centrifuged at 1200 rpm for 5 min. The 
cells were later resuspended in 3 ml PBS + 3% FCS and 1.7mL isotonic Percoll was added 
on top, followed by gentle mixing by inversion, then centrifuged at 500 rpm for 10 minutes 
without brakes. The cells were then incubated in RBC lysis buffer for 5 minutes at room 
temperature, centrifuged at 1200 rpm for 5 minutes. The cells were resuspended in 1mL 
complete media and counted by Trypan Blue exclusion assay to determine the total number 
of live cells. 
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The single cell suspensions for the spleen and the thymus were prepared in complete media 
by meshing through 70 µm and 40 µm sieve in tandem and centrifuged at 1200 rpm for 5 
minutes. The cells were incubated with RBC lysis buffer and centrifuged at 1200 rpm for 
another 5 minutes. The pellets were washed once with complete media and resuspend in 
5mL media, then the cells were counted.  
All the organ single cell suspensions (about 1x106cells/well) were stained with either 
myeloid antibody mix (575V Viability dye, CD64 PeCy7, Ly6C PercP-Cy5.5, Cd11b 
V450, MHC II A700, CD103 PE, CD11c APC, SiglecF APC-Cy7, Ly6G FITC) or 
lymphoid antibody mix (575V Viability dye, CD4 V500, CD44 PE, NK1.1 APC-Cy7, CD3 
A700, CXCR5 PeCy7, CD62L V450, TCRγδ PE-Texas Red, CD19 PercP-Cy5.5, CD8 
APC, KLRG1 BV786, PD-1 FITC, Ki67 PE, all from BD Biosciences) for flow cytometry 
analysis of various immune cell populations and their activation status. The samples were 
acquired with BD LSRII and analysed using FlowJo™ Software version 10.6. 
9. Intracellular staining of liver and spleen single cells  
Liver and spleen single cells (3 and 7 dpi, 2x106 cells/well) were seeded on a 96-well U-
bottom plate 200µL/well. The cells were either stimulated with 20ng/mL PMA, 1µg/mL 
ionomycin and 2µM monensin or left unstimulated. Monensin was used to block the 
secretion of intracellular cytokines into the media. The cells were then incubated for 6 
hours at 37oC. The cells were transferred into a V-bottom plate and centrifuged at 500g for 
5 minutes at 4oC and washed the cells with 1xPBS. We stained the cells with extracellular 
antibodies (575V viability dye, CD3 PerCP, CD4 BV510 and CD8 APC), then 
permeabilized the cells for 30 minutes at 4oC. We then stained the cells with intracellular 
antibodies (TNF PE, IFN-γ A700, perforin FITC and granzyme B V450, all from BD 
Biosciences) for 45 minutes at 4oC in the dark. We performed flow cytometry acquisition 
using BD LSRII and analysed using FlowJo™ Software version 10.6. 
10.  Splenocyte re-stimulation for cytokines ex vivo 
To re-stimulate splenocytes, we pre-coated a 48-well plate with 100µL anti-CD3 
(20µg/mg) and incubated the plate at 37oC for 30 minutes. After incubation, we pipetted 
out the anti-CD3 and added 1x106 cells/well from spleen single cells of 3- and 7-day 
infected mice. We infected or stimulated the cells with heat-killed LM (HKLM) with a 
MOI of 1:10 and left cells in media. The plate was then incubated at 37oC for 72 hours. 
After 72 hours, the plate was centrifuged at 1200 rpm for 5 minutes to separate any floating 
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cells and supernatants were collected into a new plate. We measured IFN-γ, IL-2, IL-4, IL-
17, IL-10 and TGF-β secretion by re-stimulated splenocytes by cytokine ELISA. 
11. Generation of Bone marrow-derived macrophages 
Bone marrow-derived macrophages (BMDMs) were generated by flushing out bone 
marrow precursor cells from the mice tibia and femur bones. The cells were cultured at a 
concentration of about 13x106cells/mL in 150 cm2 sterile tissue culture grade CellStar 
(Greiner Bio-One) petri dishes with 50mL of macrophage differentiation media (DMEM 
containing 10% heat inactivated fetal calf serum, 5% heat inactivated horse serum, 30% 
L929 conditioned medium, 2mM L-glutamine, 1 mM Na-pyruvate, 100 µg/ml penicillin-
streptomycin and 50µM β-mercaptoethanol) . The cells were incubated at 37oC for 10 days 
under 5% CO2 conditions with 50 ml macrophage differentiation media top-up on day 5. 
12. Infection of macrophages and determination of bacterial growth 
BMDM infection with L. monocytogenes: On day 10, macrophages were harvested and 
seeded 2x105cells per well in 96-well plates for infection with L. monocytogenes. The cells 
were stimulated with 100nM LTD4 (Sigma Aldrich) or left unstimulated (unless stated 
otherwise) overnight at 37oC under 5% CO2 conditions.  
Cells were then infected with L. monocytogenes with a multiplicity of infection (MOI) of 
10 and incubated at 37oC for 1, 3, 6 and 12 hours for determination of intracellular bacterial 
load. The supernatants were collected at each time point and stored at -20oC for 
downstream ELISA applications.  
Cells were lysed by adding 100µL 0.1% Triton X-100 in PBS and incubated at room 
temperature for 5 minutes to facilitate the release of intracellular bacteria. The lysates were 
serially diluted in 1x PBS and plated on TSA plates. The plates were incubated at 37oC 
overnight and the colony forming units (CFUs) counted to determine bacterial burden. 
13. Cytokine and Nitric oxide produced by macrophages post L. monocytogenes 
infection 
Supernatants were thawed and cytokines such as TNF, IL-1α, IL-6, IL-12p40, and IL-10 




14. RNA Extraction  
To extract RNA, tissue single cells or BMDMs were collected in 500µL Trizol. 1/5 volume 
of chloroform:isoamyl alcohol (49:1) mixture was added and vigorously mixed for 10 
seconds and incubated for 2 minutes at room temperature. The samples were then 
centrifuged at 4oC for 10 minutes at maximum speed (18000 rpm). The aqueous phase was 
removed and added into new tubes, half the amount of the original Trizol volume of 
chloroform:isoamyl was added and incubated for 2 minutes on ice. The samples were then 
centrifuged at 4oC at maximum speed. The aqueous phase was transferred into new tubes 
and added 1/10 volume of sodium acetate, linear polyacrylamide (1µL/1mL Trizol) and 
isopropanol (half of the original Trizol volume). The samples were incubated at -20oC 
overnight to precipitate the RNA. The next day, the samples were centrifuged at maximum 
speed for 20 minutes at 4oC and supernatants were removed without disturbing the RNA 
pellets. The pellets were washed using ice cold 70% ethanol (as original Trizol volume), 
and vortexed to resuspend the pellets. The samples were centrifuged at 4oC for 10 minutes 
at 7000g, removed the supernatants and washed with 500µL 70% ethanol and vortexed to 
mix. The resuspended RNA pellets were centrifuged again at 7000g for 10 minutes to 
remove excess salts. The pellets were air dried until the they were clear without over drying 
them. The pellets were resuspended in RNAse-free water and incubated at 60oC for 10 
minutes, with flicking every few minutes. The RNA concentration was measured using the 
ThermoFisher NanoDrop One UV Spectrophotometer. 
15. Quantitative Real-time PCR 
The cDNA from BMDMs and organ single cells were synthesized by using Transcriptor 
First Strand cDNA Synthesis Kit from Roche according to manufacturer’s instructions. 
Quantitave RT-PCR was done to confirm the gene expression of Cysltr1, Cysltr2 and Ltc4s 
in the samples using specific set of primers represented in the table below. 
Table 1: Set of primers used for the quantification of Cysltr1, Cysltr2 and Ltc4s 
mRNA expressions by qPCR. 
Prime
r name 
























16. Statistical analysis 
All the data was analysed using GraphPad Prism version 8.0.2, statistically analysed using 
unpaired student t-test unless stated otherwise in figure legends. A P-value under 0.05 was 




CHAPTER 3: RESULTS 
3.1. Expression of CysLT receptors and Ltc4s during Listeria monocytogenes infection 
Cysteinyl leukotriene receptors (CysLTR1 and CysLTR2) are known to be involved in 
allergic responses (106–108, 133), however, it is unknown whether CysLTs play a role in 
bacterial infection. To determine whether bacterial infection could induce expression of 
CysLT receptors and the enzyme responsible for CysLT production, we infected mice with 
L. monocytogenes and measured mRNA expression of Cysltr1, Cysltr2 and leukotriene C4 
synthase (Ltc4s) in the liver and spleen. We investigated the mRNA expression of these 
genes in the liver and spleen since L. monocytogenes mostly disseminates in these organs 
(9, 48, 139). L. monocytogenes infection in mice resulted in an upregulation in Cysltr1, 
Cysltr2 and Ltc4s mRNA expression in the liver and spleen (Figure 1A and 1B), mostly at 
later stages of infection, suggesting that CysLT signalling might be affected during the later 
stages of Listeria infection in mice. We further investigated this effect at a cellular level to 
determine whether LM could induce the expression of these genes in bone marrow-derived 
macrophages (BMDMs). As in vivo, Cysltr1 and Ltc4s mRNA expression was upregulated 
at 3 hours post-infection in macrophages (Figure 1C), however in contrast to in vivo, 
Cysltr2 expression in BMDMs remained unaffected in vitro. At a macrophage level, cysLT 
signalling is affected at early stages of LM infection. 
We were able to show that LM infection in mice and macrophages can induce Cysltr1, 
Cysltr2 and Ltc4s expression, we further asked whether this was dependent on live LM or 
its antigen was sufficient to activate CysLT signalling. We then infected BMDMs with 
heat-killed LM (HKLM) and measured mRNA expression of these genes. Interestingly, 
HKLM modestly increased Cysltr1 mRNA expression at 3 hours whereas downregulated 
at 12 hours post-infection, while it downregulated Cysltr2 and had no effect on Ltc4s 
mRNA expression (Figure 1D). These results suggest that viable L. monocytogenes is 




Figure 1: Expression of CysLT receptors and LTC4S during Listeria monocytogenes infection 
in mice and macrophages. C57BL/6 wild-type mice were infected with 7.5x10
5 
colony forming 
units (CFUs)/200µL LM intraperitoneally and sacrificed at the indicated time-points. a) spleen and 
the b) liver were collected from each mouse for each time point for RNA extraction and measured 
mRNA expression of Cysltr1, Cysltr2, and Ltc4s (n = 3 mice per group). Bone marrow-derived 
macrophages (BMDMs) from C57BL/6 wild-type mice were generated and infected with c) live 
LM or d) heat-killed LM (HKLM) with a multiplicity of infection (MOI) of 50 and collected RNA 
samples at different time-points (0, 1, 3, 6  and 12 hours post-infection) to measure Cysltr1, Cysltr2, 
and Ltc4s expression. Error bar denotes mean ± SEM and analysed using the One-way ANOVA 
multiple comparison test (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
 
3.2. Generation of CysLTR1 knockout mice 
CysLTR1 deficient mice were generated using a homologous recombination technique by 
replacing the 278 nucleotides of the CysLTR1 coding region with a neomycin resistance 
gene cassette (Figure 2A) (137). The mice were gifted by Dr. Yoshihide Kanaoka (Harvard 
University, USA) as CysLTR1 deficient on pure BALB/c and C57BL/6 backgrounds. We 
crossed the mice with our lab’s BALB/c and C57BL/6 mice and confirmed the CysLTR1 
deletion by PCR (Figure 2B). The wildtype specific primers were unable to amplify the 
knockout mice samples, while our CysLTR1 deletion specific primers were able to amplify 
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the mutant gene (333 bp) from deficient mice, confirming that CysLTR1 was deleted in 
our knockout mice.  
 
 
Figure 2: Generation of CysLTR1 deficient mice and confirmation of deletion. A) The 
generation of CysLTR1 deficient allele by homologous recombination, the upper structure 
represents the genomic arrangement of the mouse CysLTR1 gene, the middle is the targeting vector, 
and the lower structure represents the organization of the putative recombinant CysLTR1 allele.  B) 




3.3. Characterization of CysLTR1 deficient mice  
Characterization of CysLTR1 Knockout mice and phenotypic analysis: CysLTR1 
mice were generated by Kanaoka’s group (137), however, full characterization of the mice 
has not been reported yet. Here, we report whether the deletion of CysLTR1 has any effects 
on homeostasis at naïve state. To examine this, we characterized 8-12-week-old C57BL/6 
CysLTR1-/- and CysLTR1+/+ (littermate controls) mice. At naïve state, there were no 
difference in body weights, organ weights or cell numbers between the two groups (Figure 
3A-3C). We then validated the CysLTR1 deletion on mice organs by qPCR, and there was 
no mRNA expression of CysLTR1 in the thymus, spleen, liver, and lung of knockout mice. 
We then wanted to investigate whether CysLTR1 deletion influenced mRNA expression 
of the other cysLT receptor and enzyme responsible for the synthesis of cysLTs in these 
animals. As expected, there were no significant differences in the mRNA expression of 
Cysltr2 and Ltc4s between the knockout mice and their littermate controls (Figure 3D-3F). 
Cysltr1 and Cysltr2 genes are localized on different chromosomes, chromosomes X and 14 
on the mouse genome respectively (137), therefore the deletion of one gene should not 
affect the expression of the other unless there are unknown feedback mechanisms. 
CysLTR1 knockout mice on BALB/c background, were characterized by Paballo Mosala, 
PhD candidate in our lab (manuscript in preparation). 
 
Figure 3: Characterization of CysLTR1 deficient mice. CysLTR1 deficient mice were sacrificed 
and characterized for any differences at naïve state by (n =5-6 per group), A) total body weight, 
B) organ weight. C) The organs were collected for single-cell suspension, total cell numbers were 
counted for each tissue. From the single-cell suspensions, we collected 2x106 cells for RNA 
extraction. The mRNA expression of D) Cysltr1 (to confirm deletion), E) Cysltr2 and F) Ltc4s was 
measured by qPCR. Data is representative of three experiments.  Error bars denote mean ± SEM 
and analysed using the unpaired student t-test with Welch’s correction, ****p<0.0001. 
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Thymic generation of lymphocytes is not affected by CysLTR1 deletion: We confirmed 
that Cysltr1 was successfully deleted in our knockout mice, and the deletion of Cysltr1 had 
no effect on Cysltr2 and Ltc4s expression. We then wanted to determine whether Cysltr1 
deletion had any effect at homeostasis. The thymus is the organ where the development 
and maturation of lymphocytes occurs and therefore, we wanted to see whether deletion of 
CysLTR1 had any effect in the development of these cells at naïve state by flow cytometry 
(gating strategy in Supplementary Figure S1). There were no differences in the thymus T 
cell percentages and cell numbers (Figure 4A-B).  
Deletion of CysLTR1 has no effect on lung pathology and immune cells at naïve state: 
We then wanted to determine what effect CysLTR1 deletion has on the lung pathology and 
at the cellular level. We performed lung histopathology on CysLTR1 KO (knockout) mice 
and their littermate controls at naïve state and showed that the deletion of CysLTR1 does 
not have an effect on lung pathology (Figure 5A) nor the free lung alveolar spaces (Figure 
5B). Consistent with Mao et al. 2018, who generated CysLTR1 knockout mice using 
CRISPR/Cas9 and also demonstrated that the deletion of this gene had no significant effect 
on lung pathology (140). The lung lymphocyte populations (B, NK, CD8 T, and CD4 T 
cells) had no significant differences in both cell percentages and cell numbers between the 
knockouts and their littermate controls (Figure 5C-D). Furthermore, within CD4 and CD8 
T cell subsets (CD62L+ CD44-: naïve; CD62L+ CD44+: central memory; CD62L- CD44+: 
effector/effector memory or activated cells; and CD62L- CD44-: double negative cells) 
there were no significant differences (Figure 5E-F). We also looked at T cell exhaustion 
and homing markers (PD1 and KLRG1, respectively), KO lung CD4 T cells had 
significantly reduced PD1+ KLRG1+ and PD1+ KLRG1- but increased PD1- KLRG1- CD4 
T cells (Figure S7A). There was a significant reduction in KO PD1+ KLRG1+ CD8 T cells 
at naïve state (Figure S7B) indicating that KO CD4 and CD8 T cells in the lung have less 
proliferative capacity (141). The myeloid cell populations (neutrophils, interstitial 
macrophages (macs), eosinophils, alveolar macs, monocyte-derived dendritic cells (DCs), 
CD11b DCs, CD103 DCs, and monocytes) also had no significant differences at naïve state 
(Figure 5G-H). 
We then measured cytokines in the lung homogenates at naïve state to determine whether 
the deletion influenced the ability of cells to release cytokines at naïve state in knockout 
mice. There were no significant differences in most of the pro-inflammatory cytokine (IL-
12p40, IL-12p70, IL-6, IL-2, TNF, IL-1α and IL-1β) we measured (Figure 5I), however, 
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IFN-γ and IL-17 were reduced in our knockout mice. This reduction was not   observed in 
the repeat experiments, indicating that it might likely be due to an artefact on the 
experiment. The lung anti-inflammatory (IL-4, IL-5, and IL-13); regulatory (IL-10 and 
TGF-β) cytokines, chemokine (RANTES or CCL5) and growth factor (GM-CSF) had no 
significant differences (Figure 5J-L). In the study conducted by Mao et al. 2018, they also 
demonstrated that nitric oxide production was affected by the deletion of CysLTR1 in the 
lung tissue and they also further showed this by measuring the protein expression of the 
nitric oxide mediator, DDAH1 by western blot. Both NO and DDAH1 were both reduced 
in their CysLTR1 knockout mice (140). However, nitric oxide levels in the lung in our 
CysLTR1 KO mice were not affected (Figure 5M). These results demonstrate that at naïve 
state, CysLTR1 has no major effect on lung pathology, recruitment of the immune cell 
populations, cytokines and nitric oxide secretion.  
 
Figure 4: CysLTR1 deletion has no effect on thymic lymphoid cell populations. Thymus T cell 
generation was determined by CD4high CD8low, CD4low CD8high, CD4high CD8high and CD4low CD8low 
using flow cytometry from total live cells. Data is representative of three experiments (n=5-6 
mice/group). Error bars denote mean ± SEM and analysed using the unpaired student t-test 





Figure 5: CysLTR1 deletion has no effect on lung homeostasis. CysLTR1 knockout and their 
littermate control mice were sacrificed at naïve state (n=5-6 mice per group) and the lung tissue 
was harvested for histology, flow cytometry, and ELISA. A) H&E staining of the lung for CysLTR1 
KO and WT mice. B) Lung free alveolar air space quantification. C-D) Lung lymphoid cell 
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percentages of total live cells and cell numbers measured by flow cytometry. E-F) CD4 T cell and 
CD8 T cell subsets measured by flow cytometry. G-H) Myeloid cell percentages of total live cells 
and cell numbers. I) pro-inflammatory, J) Th2, K) regulatory cytokines, L) growth factor and 
chemokine by ELISA and M) nitric oxide from lung homogenates. Data is representative of three 
experiments.  Error bars denote mean ± SEM and analysed using the unpaired student t-test 
with/without Welch’s correction, *p<0.05, **p<0.01. 
 
Liver pathology and homeostasis is not affected by CysLTR1 deficiency: The role of 
CysLTR1 has been mostly demonstrated in lung pathology and airway etiology because of 
its role in allergic and asthmatic responses. Because we are interested in the role of 
CysLTR1 during LM infection, we needed to determine whether the deletion of this 
receptor had any effect in pathology and the immune population at naïve state in the organs 
that are important during LM infection. We then looked at the effect of CysLTR1 deletion 
in the liver. Like in the lung, haematoxylin and eosin (H&E) staining showed no differences 
in the liver pathology of the KO and WT mice (Figure 6A). Flow cytometry analysis of the 
liver lymphoid cell percentages and numbers exhibited no differences between the KO and 
WT mice (Figure 6B-C). The CD4 and CD8 T cell subsets and follicular Th cells also had 
no differences at naïve state (Figure 6D-E). There were no differences between the 
percentages of WT and KO PD1 and KLRG1 expression by CD4 and CD8 T cells in the 
liver (Figure S7C-D). The myeloid cell population also had no significant differences 
(Figure 6F-G). However, like in the lung, we observed a reduction of IL-17 in the KO liver 
while all the other cytokines had no differences (Figure 6H). There were no differences in 
anti-inflammatory cytokine (IL-4, IL-5, and IL-13) and regulatory cytokines (IL-10 and 
TGF-β) (Figure 6I-J). However, there was a reduction in GM-CSF levels in KO liver 
homogenates compared to their littermate controls (Figure 6K). The nitric oxide production 
was not affected by CysLTR1 deletion (Figure 6L). These results demonstrate that the 




Figure 6: CysLTR1 deletion has no effect on liver pathology and immune cellular responses 
at the naïve state. CysLTR1 knockout and their littermate control mice were sacrificed at naïve 
state (n=5-6 mice per group) and the liver was harvested for histology, flow cytometry, and ELISA. 
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A) H&E staining of the liver for CysLTR1 KO and WT mice. B-C) Liver lymphoid cell percentages 
of total live cells and cell numbers measured by flow cytometry. D-E) CD4 T cell and CD8 T cell 
subsets measured by flow cytometry. F-G) Myeloid cell percentages of total live cells and cell 
numbers. H) pro-inflammatory, I) Th2, J) regulatory cytokines, K) growth factor (GMCSF) and 
chemokine (RANTES) by ELISA and L) nitric oxide from liver homogenates. Data is 
representative of three experiments.  Error bars denote mean ± SEM and analysed using the 
unpaired student t-test with/without Welch’s correction, **p<0.01. 
 
CysLTR1 deficiency in mice has no effect on spleen pathology and immune cells at 
naïve state: Similar to lung and liver, we then determined the effect of CysLTR1 deletion 
on the mouse spleen and immune cell populations at naïve state. The H&E staining showed 
no differences between the CysLTR1 KO and WT mice spleen (Figure 7A). There were no 
differences in the lymphoid cell percentages and numbers between the two groups (Figure 
7B-C). Similarly, CD4 and CD8 T cell subsets showed no differences in the percentages 
(Figure 7D-E). As expected, the naïve CD4 T cells (CD62L+ CD44-) were higher in both 
groups at a steady state. Exhaustion markers expressed by CD4 and CD8 T cells were 
comparable between KO and WT spleen cells, with the exception of PD1- KLRG1+ CD8 
T cells that were significantly increased in KO mice (Figure S7E-F) which indicates 
increased CD8 T cells in the spleen vasculature (142). The myeloid cell population 
demonstrated no differences both in cell percentages and cell numbers between the two 
groups (Figure 7F-G). The marginal zone macrophages were the least frequent myeloid 
cells in both groups. These results show that CysLTR1 deletion has no effect on mice 
spleen pathology and immune populations at naïve state. 
 
Systemic cytokine and antibody production are not affected by CysLTR1 deletion: 
We then determined systemic cytokines and antibodies secreted in the blood at naïve state 
to evaluate whether the deletion of CysLTR1 might influence their secretion. There were 
no differences in cytokine secretion between the knockouts and their littermate controls 
(Figure 8A). However, we found a modest increase in total IgG and a reduction in IgG3 in 
the knockout mice (Figure 8B). These differences were not maintained when the 
experiment was repeated, therefore, CysLTR1 deletion has no effect on antibody and 
cytokine secretion at naïve state. Together, these results demonstrate that CysLTR1 






Figure 7: CysLTR1 deletion has no effect on spleen pathology and immune cell populations 
at naïve state. CysLTR1 knockout mice and their littermate control mice were sacrificed at naïve 
state (n=5-6 mice per group) and the spleen was harvested for histology and flow cytometry 
analysis. A) H&E staining of the spleen for CysLTR1 KO and WT mice. B-C) Spleen lymphoid 
cell percentages of total live splenocytes and cell numbers measured by flow cytometry. D-E) CD4 
T cell and CD8 T cell subsets measured by flow cytometry. F-G) Myeloid cell percentages of total 
live splenocytes and cell numbers. Data is representative of three experiments. Error bars denote 






Figure 8: CysLTR1 deletion has no effect on serum cytokine and antibody production at naïve 
state. CysLTR1 knockout mice and their littermate control mice were sacrificed at naïve state (n=5-
6 mice per group) and cardiac puncture was performed to collect blood for antibody and cytokine 
measurement. A) Measured cytokine (IL-4, IFN-γ, TNF, IL-10 and IL-6) and B) antibody (IgG1, 
IgG2b, IgG, IgA, IgM, IgG3, IgE and IgG2a) levels in the serum by ELISA. Data is representative 
of three experiments. Error bars denote mean ± SEM and analysed using the unpaired student t-test 
with/without Welch’s correction, *p<0.05. 
 
3.4. CysLTR1-deficient macrophages revealed similar bacterial growth during L. 
monocytogenes infection 
We showed that CysLTR1 deletion at naïve state has no effect on the mouse homeostasis, 
suggesting no baseline defect in these animals. Our findings also demonstrated an 
upregulation of CysLTR1 in wildtype mice and macrophages, suggesting that this receptor 
might have an LM specific role. Therefore, we sought to investigate whether deletion of 
this receptor has any role in the control of LM infection in vitro. We generated BMDMs 
from C57BL/6 and BALB/c CysLTR1+/+ (wildtype/WT) and CysLTR1-/- (knockout/KO) 
mice and then infected with LM. Macrophages can phagocyte and ingest invading 
pathogens, present antigens to T cells, and induce the production of cytokines that are 
required for the activation of other immune cells (143). We, therefore, wanted to determine 
the ability of the macrophages to phagocyte the bacteria by measuring ingested bacteria 
from BMDM lysates at different time points. 
We found that there were no differences in the bacterial burden in KO and WT BMDMs in 
both backgrounds (Figure 9A-B). In addition, the ability of the macrophages to phagocyte 
LM was not affected by the deletion of CysLTR1 in both backgrounds determined at 1-hour 
post-infection.  We then wanted to determine whether the secretion of cytokines and nitric 
oxide (NO), required for the effective killing of intracellular bacteria, was impaired in 
CysLTR1 KO macrophages. We measured NO production, cytokine and chemokine 
secretion at 6- and 12-hours after infection. Reactive nitrogen intermediates (RNI) such as 
NO synthase (NOS) have been shown to play a role in inhibiting the escape and growth of 
LM in macrophages (46, 144, 145). There were no differences in NO secretion by 
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CysLTR1-/- and CysLTR1+/+ macrophages in both BALB/c and C57BL/6 (Figure 9C and 
9E). We found that C56BL/6 knockout macrophages tend to increase in IL-10 secretion 
(Figure 9D), while BALB/c KO macrophages had a decreasing trend in the secretion of IL-
10 (Figure 9F) post LM infection. At 12 hours post-infection, TNF secretion had a 
decreasing trend in both C57BL/6 KO BMDMs (Figure 9G) and BALB/c BMDMs (Figure 
9I). The IL-6 secretion in C57BL/6 KO BMDMs at 12 hours post-infection had an 
increasing trend (Figure 9H), and in contrast it showed a decreasing trend in KO BALB/c 
macrophages (Figure 9J). MIP2 secretion in KO C57BL/6 (Figure 9K) and KO BALB/c 
(Figure 9M) macrophages was decreased. Macrophages from C57BL/6 (Figure 9L) and 
BALB/c (Figure 9N) had no major difference on RANTES/CCL5 secretion between the 
KO and wildtype macrophages post LM infection. In summary, CysLTR1 deletion had no 
effect on intracellular growth of LM, cytokine and chemokine as well as nitric oxide 
production. The differential cytokine secretion observed in macrophages could be due to 





Figure 9: CysLTR1 knockout macrophage control of LM infections and secreted cytokines. 
C57BL/6 and BALB/c BMDMs from CysLTR1 wildtype and knockout mice were generated for 
10 days and infected with 2x10^5 CFUs LM for 1 hour, 3, 6 and 12 hours. A-B) Bacterial burden 
was measured in macrophages by plating CFUs. C&E) Nitric oxide in supernatants. D&F) IL-10, 
G&I) TNF, H&J) IL-6, K&M) MIP2 and L&N) RANTES were measured from cell supernatants 
using ELISA. Data is a representative of quadruplicates and two pooled experiments. Error bar 
denotes mean ± SEM and analysed using the unpaired student t-test, *p<0.05. 
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3.5. CysLTR1 is dispensable during L. monocytogenes infection in mice 
CysLTR1 deficiency result in increased liver neutrophils and monocytes during LM 
infection: Thus far, we have established that CysLTR1 deletion has no effect on mice at 
naïve state, and it does not have an effect on intracellular growth bacteria in macrophages 
in vitro. We then investigated whether the deletion of this receptor affects host protection 
during LM infection in vivo. We infected CysLTR1 KO and WT mice with LM and 
sacrificed at three- and seven-days post-infection (3- and 7-dpi). At each time point, we 
measured the bacterial burden in liver and spleen. In the liver, we found no differences in 
bacterial loads at both 3- and 7-dpi (Figure 10A). At 3dpi, the KO mice had increased liver 
cell numbers, but not at 7-dpi (Figure 10B) and liver weights (Figure 10C) were 
comparable to their littermate controls. Furthermore, histopathology analysis of the liver 
showed that there were no differences in lesion areas between the wildtype and knockout 
mice (Figure 10D and 10E) at both time points. We then measured immune cell recruitment 
by flow cytometry in the liver (gating strategy in Figure S2 and S4). Myeloid cells are a 
crucial part of the immune system as they initiate the innate immune responses during host 
invasion by pathogens and play an important role in the activation of adaptive immunity. 
Three days post-infection, neutrophil cell percentages in KO mice were significantly 
increased during LM infection while there were no significant differences in other myeloid 
cell populations (Figure 10F). In CysLTR1 KO livers the absolute numbers of monocytes 
and neutrophils were significantly increased compared to littermate controls 3 days post-
LM infection (Figure 10H). At 7 days of post-LM infection, there were no differences in 
myeloid cell percentages except for an increase in monocyte-derived macrophage 
percentages in KO mice (Figure 10G). However, there were no observed differences in the 
myeloid cell numbers (Figure 10I). These results show that CysLTR1 deficiency results in 




Figure 10: CysLTR1 deficiency in mice increased liver neutrophils early after L. 
monocytogenes infection. CysLTR1 KO mice and their littermate controls were infected with 
about 1.1x105 LM CFUs/200µL per mouse intraperitoneally. The mice were sacrificed at 3- and 7-
dpi (n = 6 mice per group) and the liver were collected to measure A) bacterial burden by plating 
liver homogenates on tryptic soy agar (TSA) plates for CFUs, B) cell numbers by making single-
cell suspensions,  C) organ weights and D) H&E staining for immunohistology analysis. E) liver 
lesions were measured using the Olympus-VS-ASW-L100 imaging system, lesions are indicated 
by the circles. The single cells were then stained for myeloid cell population analysis by flow 
cytometry. F-G) Liver myeloid cell percentages of live cells 3- and 7-dpi. H-I) Liver myeloid cell 
numbers 3- and 7-dpi. Data is representative of two experiments.  Error bars denote mean ± SEM 
and analysed using the unpaired student t-test with Welch’s correction, (*p<0.05, **p<0.01). 
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CysLTR1 deficient mice have reduced B cell, NK cell and CD4 T cell percentages at 
early stages of infection with LM: We then analysed the lymphoid cell populations since 
they are important for the normal function of the immune system. In the liver lymphoid 
cell percentages at the 3 days post-LM infection, we observed a significant reduction in B 
cells, NK cells and CD4 T cells in KO mice while there were no differences in other cell 
populations (Figure 11A), however, cell numbers had no significant differences except for 
γδ T cells (Figure 11C). At 7dpi, we observed no differences in the lymphoid cell 
percentages (Figure 11B), however, CD8 T cell numbers were significantly increased in 
KO mice (Figure 11D). We then looked at CD4 and CD8 T cell subsets post-infection, at 
3dpi there were no differences in CD4 T cell subsets (naïve, central memory, and 
effector/effector T cells) and at 7dpi there were no differences in naive and effector/effector 
CD4 T cells, while there was a significant decrease in central memory CD4 T cells (Figure 
11E and 11F). The CD8 T cell subsets both at 3- and 7dpi had no differences except 
increased effector/effector memory cells at 3 dpi (Figure 11G and 11H). We also looked at 
exhaustion and homing of CD4 and CD8 T cells at 3- and 7-days post-LM infection using 
exhaustion and parenchymal markers PD1 and KLRG1, and found no differences in CD4 
exhausted T cells at 3dpi  (Figure S8A), and at 7dpi there were a significant reduction in 
vascular, less differentiated PD1- KLRG1+ KO cells (Figure S8B). There was a significant 
increase in parenchymal PD1+ KLRG1+ cells and reduction in PD1- KLRG1- KO CD8 T 
cells 3dpi (Figure S8C), while there were no differences in CD8 T cell exhaustion at 7dpi 
(Supplementary Figure S8D). Furthermore, we determined T cell proliferation by 
measuring Ki67 expression. At 3- and 7-dpi, CD4 and CD8 T cell proliferation showed 
similar proliferation between the two groups of animals (Figure 11I and 11J). This suggest 




Figure 11: Effect of CysLTR1 deletion in liver lymphocyte population post-L. monocytogenes 
infection. CysLTR1 deficient mice and their littermate controls were infected with about 1.1x105 
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LM CFUs/200µL per mouse intraperitoneally and sacrificed the mice at 3- and 7-dpi (n = 6 per 
group). Liver single cells were stained for the lymphoid cell population for analysis by flow 
cytometry. A-B) Liver lymphoid cell percentages of total live cells, C-D) lymphoid cell numbers, 
E-F) CD4 T cell subsets, G-H) CD8 T cell subsets and I-J) CD4 and CD8 T cell proliferation 
measured by Ki67 at 3- and 7-dpi. Data is representative of two independent experiments.  Error 
bars denote mean ± SEM and analysed using the unpaired student t-test with Welch’s correction, 
(*p<0.05). 
 
CysLTR1 deficiency increased T cell specific host responses after L. monocytogenes 
infection in mice: To explore cell-specific cytokine responses, we re-stimulated liver 
single-cell suspensions with phorbol myristate acetate (PMA) and ionomycin 
(PMA/ionomycin) or left untreated for 6 hours to measure cytokine (IFN-γ and TNF), pore-
forming protease (perforin) and serine protease (granzyme B) secretion by CD4 and CD8 
T cells 3- and 7-days post-LM infection by flow cytometry (using the gating strategy in 
Figure S6). PMA/ionomycin is used for activation of the transcription factors NF-KB and 
NFAT which lead to cytokine secretion by T cells (146). We chose secretion of these 
cytokines and proteins by T cells because they have been shown to play a protective role 
during L. monocytogenes infection (147–154). There was no effect on IFN-γ production by 
CD4+ T cells regardless of stimulation (Figure 12A), whilst IFN-γ was significantly 
reduced in CD8+ T cell production in mice lacking Cystlr1 (Figure 12B). There was a 
significantly increased production of perforin and granzyme B in CD8 T cells in 
unstimulated KO liver cells, but not with PMA/ionomycin stimulation (Figure 12C and 
12D). Granzyme B and perforin have been shown to be produced mostly by CD8+ T cells. 
At 7dpi, IFN-γ production by CD4+ T cells was significantly increased after 
PMA/ionomycin stimulation in KO mice (Figure 13A). We also measured TNF production 
in CD4+ T cells at 7dpi, and there was a significant increase in TNF secretion in 
unstimulated cells, and an increasing trend in PMA/ionomycin cells (Figure 13B).  
Collectively, these results suggest that liver CD4 and CD8 T cells from CysLTR1 KO mice 
have a general trend of increased cytotoxic and IFN-γ and TNF secretion except for 




Figure 12:  Liver CD8 T cells from CysTLR1 deficient mice have increased perforin and 
granzyme B production early after LM infection. CysLTR1 deficient mice and their littermate 
controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice 
were sacrificed at 3dpi (n = 6 per group). Liver single cells were stimulated for cytokine production 
using PMA/ionomycin (stimulated) or left unstimulated. Flow cytometry was used to determine 
percentages of A-B) IFN- γ produced by CD4 and CD8 T cells, C) perforin and D) granzyme B by 
CD8 T cells 3dpi. Error bars denote mean ± SEM and analysed using the unpaired, student t-test 






Figure 13: Liver CD4 T cells from CysLTR1 deficient mice have increased production of IFN- 
γ and TNF after L. monocytogenes infection. CysLTR1 deficient mice and their littermate 
controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and sacrificed at 
7dpi (n = 6 per group). Liver single cells were stimulated for cytokine production using 
PMA/ionomycin (stimulated) or left unstimulated. Flow cytometry was used to determine 
percentages of A) IFN- γ and B) TNF produced by CD4 T cells at 7dpi. Error bars denote mean ± 
SEM and analysed using the unpaired student t-test with Welch’s correction, (*p<0.05). 
 
CysLTR1 deficiency results in decreased pro-inflammatory cytokines at early LM 
infection: We then measured nitric oxide, cytokines (pro-inflammatory, regulatory and 
Th2 cytokines), chemokines and growth factors at 3- and 7-days post-LM infection in liver 
homogenates. There were no significant differences in NO production in the liver at both 
time-points (Figure 14A). The IL-1α production was significantly increased in liver 
homogenates at 7dpi (Figure 14B), whilst IL-1β remained unaffected (Figure 14C) in the 
KO mice.  There was a significant increase of IFN-β at 7dpi in liver homogenates (Figure 
14D) of KO mice. IFN-γ, IL-17, and IL-12p70 production were significantly reduced in 
KO mice at 3dpi while there were no differences at 7dpi (Figure 14E, 14F, and 14I). There 
were no differences in other proinflammatory cytokines; IL-6 and IL-12p40 between the 
KO and their littermate controls (Figure 14G and 14H). We also assessed the regulatory 
(TGF-β and IL-10) and Th2 (IL-4) cytokines, and there were no significant differences in 
TGF-β, IL-10 and IL-4 production between the two groups (Figure 14J-14L). We then 
measured chemokines and growth factors and found a significant reduction in CXCL2, 
CXCL10, and GM-CSF production at 3dpi (Figure 15A, 15F, and 15H) whereas CCL3 and 
CXCL1 production were increased at 7dpi (Figure 15C and 15D) by KO mice. However, 
at later stages of the infection, these differences were not observed instead, KO mice have 
increased CCL3 and CXCL1 levels. Overall, these results suggest that at the early stages 
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of infection there are slight decrease in the levels of Th1 (IL12p70, GM-CSF), Th17 (IL17) 




Figure 14: Nitric oxide, pro-inflammatory, regulatory and Th2 cytokine levels in the liver of 
CysLTR1 knockout mice after L. monocytogenes infection. CysLTR1 deficient mice and their 
littermate controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and 
sacrificed the mice at 7dpi (n = 6 per group). Collected the liver for homogenates and measured 
A) nitric oxide, pro-inflammatory; B) IL-1α, C) IL-1β, D) IFN-β, E) IFN-γ, F) IL-17, G) IL-6, H) 
IL-12p40, I) IL-12p70, regulatory;  J) TGF-β, K) IL-10 and Th2 cytokines; L) IL-4 and by ELISA. 
Data is representative of three experiments. Error bars denote mean ± SEM and analysed using the 








Figure 15: Chemokine and growth factor levels in the liver of CysLTR1 knockout mice after 
L. monocytogenes infection. CysLTR1 deficient mice and their littermate controls were infected 
with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and sacrificed the mice at 3- and 7-dpi 
(n = 6 per group). Liver homogenates were collected and measured for A) CXCL2, B) 
CCL5/RANTES, C) CCL3, D) CXCL1, E) CXCL5, F) CXCL10, G) CCL2, H) GM-CSF and I) 
G-CSF concentration by ELISA. Data is representative of three experiments. Error bars denote 
mean ± SEM and analysed using the unpaired student t-test with/without Welch’s correction, 
(*p<0.05). 
 
CysLTR1 deletion results in an increased recruitment of neutrophils in the spleen 
after LM infection: The spleen plays an important role during host immune responses to 
blood-borne bacterial infections (155), due to its unique structural organization. The spleen 
can connect innate and adaptive immunity resulting in effective clearance of blood 
pathogens (156). Therefore, we then evaluated the effect of CysLTR1 deletion on the 
ability of the spleen to control LM infection in mice. CysLTR1 deficient mice were infected 
with LM and sacrificed at 3- and 7-dpi to determine the bacterial burden and immune 
responses by flow cytometry. At both time points, the KO and WT mice had comparable 
bacterial burdens in the spleen (Figure 16A). We made single-cell suspensions and found 
that at 7dpi the KO mice had significantly reduced cell numbers (Figure 16B) with no 
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apparent differences in spleen weights at both time points (Figure 16C). Even though there 
seemed to be no differences in the control of LM infection between the two mice groups, 
there seemed to be a reduction in cellular recruitment into the spleen of CysLTR1 deficient 
mice at 7dpi, a time point regarded as chronic stage of infection during LM infection. This 
revealed more tissue distraction in KO mice compared to their littermate controls indicated 
by the white pulp (black arrow) and red pulp (red arrow) atrophy (Figure 16D). White pulp 
atrophy could characterize the loss of lymphocytes in T cell and B cell areas of the spleen, 
and red pulp atrophy is due to decreased hematopoietic cells (157, 158). We then assessed 
immune cell populations in response to LM infection by flow cytometry analysis. At 3dpi, 
we saw an increasing trend in myeloid cell percentages (monocytes, red pulp macrophages, 
marginal zone macrophages, conventional DC1, and DC2) of CysLTR1 KO mice 
compared to their littermate WT controls. Moreover, we observed a significant increase in 
neutrophil percentages (Figure 17E), which were maintained in cell numbers in KO mice 
(Figure 16G), suggesting CysLT signalling might play an important role in the recruitment 
of neutrophils. At 7dpi, there were no differences in spleen myeloid cell percentages of the 
two groups, except for a significant increase in marginal zone macrophages and neutrophil 
cell percentages of KO mice (Figure 16F). Amongst myeloid cell numbers, there was a 
decreasing trend in KO cell populations, with a significant reduction in cDC1 (Figure 16H), 
this reduction in KO myeloid cell numbers could be attributed to the decreased cell 
numbers harvested from the spleen. This suggest that increased neutrophil percentages both 
at 3dpi and 7dpi can highlight the role of CysLT signalling in inflammation in both tissue 




Figure 16: CysLTR1 deficiency in mice increased splenic neutrophils after L. monocytogenes 
infection. CysLTR1 KO mice and their littermate controls were infected with about 1.1x105 LM 
CFUs/200µL per mouse intraperitoneally. The mice were sacrificed at 3- and 7-dpi (n = 6 mice per 
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group) and spleen were collected to measure A) bacterial burden by plating spleen homogenates 
on TSA plates for CFUs, B) cell numbers by making single-cell suspensions and C) organ weights. 
D) Spleen histopathology was done by staining with H&E and the images were captured using the 
Olympus-VS-ASW-L100 imaging system. The single cells were then stained for myeloid cell 
population analysis by flow cytometry. E-F) Spleen myeloid cell percentages of total live 
splenocytes at 3- and 7-dpi. G-H) Spleen myeloid cell numbers 3- and 7-dpi. Data is representative 
of two experiments.  Error bars denote mean ± SEM and analysed using the unpaired student t-test 
with/without Welch’s correction, (*p<0.05, **p<0.01). 
 
CysLTR1 deficient spleen lymphocytes are significantly decreased early after LM 
infection: We then assessed at lymphocyte population in the spleen at 3- and 7-days post-
LM infection. At 3dpi, there was a significant reduction in the KO lymphoid cell 
percentages (T cells, B cells, NK cells, CD8 T cells, and CD4 T cells) except for γδ T cells 
which were comparable to littermate controls (Figure 17A). The lymphoid cell numbers, 
however, had no differences between the KO and WT (Figure 17C). At 7dpi, the lymphoid 
cell percentages were comparable between the two groups, but the KO mice had 
significantly reduced NK cells (Figure 17B). The lymphoid cell numbers were significantly 
reduced in the KO mice compared to their controls (Figure 17D). We then looked at T cell 
subsets at 3dpi and there was no difference in CD4 follicular T helper cells, while there 
was a significant reduction in KO CD4 naïve T cells, but increased central memory T cells 
and effector-effector T cells (Figure 17E), while there were no differences in CD4 T cell 
subsets at 7dpi (Figure 17F). There was an increasing trend in KO CD8 follicular T helper 
cells, while there was a significant reduction in naïve, and central memory, but increased 
effector-effector CD8 T cells 3dpi (Figure 17G). At 7dpi however, there was only a 
significant reduction in KO CD8 central memory T cells while the other subsets had no 
differences between the two groups (Figure 17H). We measured T cell exhaustion or 
activation by looking at PD1 and KLRG1 expression by CD4 and CD8 T cells at 3- and 7-
dpi. At 3dpi, there was a significant increase in both KO CD4 and CD8 T cells expression 
of PD1+ KLRG1+ markers which indicates increased activated vascular cells, while there 
was a reduction in PD1- KLRG1- cells (Figure S9A and S9C).  However, at 7dpi, there 
were no differences between CD4 and CD8 T cell exhaustion markers between the KO and 
WT mice (Figure S9B and S9D). We measured T cell proliferation, at 3dpi KO CD8 T cell 
proliferation was significantly increased (Figure 17I), while there was a significant increase 
in KO CD4 and CD8 T cell proliferation at 7dpi (Figure 17H). These results show that 
Cysltr1 KO mice have decreased NK cells in the spleen, increased effector and proliferative 




Figure 17: Effect of CysLTR1 deletion in mice spleen lymphocyte population post L. 
monocytogenes infection. CysLTR1 deficient mice and their littermate controls were infected with 
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about 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice were sacrificed at 3- and 
7-dpi (n = 6 per group). Spleen single cells were stained for lymphoid cell population analysis by 
flow cytometry. A-B) Spleen lymphoid cell percentages of total live splenocytes, C-D) lymphoid 
cell numbers, E-F) CD4 T cell subsets, G-H) CD8 T cell subsets and I-J) CD4 and CD8 T cell 
proliferation measured by Ki67 at 3- and 7-dpi. Data is representative of two independent 
experiments.  Error bars denote mean ± SEM and analysed using the unpaired student t-test 
with/without Welch’s correction, (*p<0.05, **p <0.01, ***p<0.001). 
 
After LM infection, CysLTR1 deficient mice showed an early decrease in IFN-γ and 
a late increase in TNF production by CD4 T cells: We then stimulated splenocytes with 
PMA/ionomycin or left unstimulated to measure IFN-γ, Granzyme B, perforin and TNF 
secretion by flow cytometry. At 3dpi, the percentage of KO CD4 T cells producing IFN-γ 
were significantly reduced in unstimulated cells (Figure 18A). However, KO CD8 T cells 
producing IFN-γ were unaffected (Figure 18B). There was a significant decrease in KO 
CD8 T cells producing perforin (Figure 18C). CysLTR1 KO CD8 T cells production of 
granzyme B had no effect when compared to the WT littermate controls (Figure 18C and 
18D). At 7dpi, there was a significant increase in TNF production by KO CD4 T cells post 
PMA/ionomycin stimulation (Figure 19B) and a similar trend in IFN-γ production (Figure 
19A). Interestingly, even though CD4 and CD8 T cells have higher activation markers at 




Figure 18: CysLTR1 deficient CD8 T cells have decreased production of IFN-γ and perforin 
at three days post-L. monocytogenes infection. CysLTR1 deficient mice and their littermate 
controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice 
were sacrificed at 3dpi (n = 6 per group). Splenocytes were stimulated for cytokine production 
using PMA/ionomycin (stimulated) or left unstimulated. Flow cytometry was used to determine 
percentages of A-B) IFN-γ produced by CD4 and CD8 T cells, C) perforin and D) granzyme B by 
CD8 T cells 3dpi. Error bars denote mean ± SEM and analysed using the unpaired student t-test 
with/without Welch’s correction, (*p<0.05, **p<0.01, ***p<0.001). 
 
 
Figure 19: CysLTR1 deficient mice CD4 T cells have increased production of IFN-γ and TNF 
at seven days post-L. monocytogenes infection. CysLTR1 deficient mice and their littermate 
controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice 
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were sacrificed at 7dpi (n = 6 per group). Splenocytes were stimulated for cytokine production 
using PMA/ionomycin (stimulated) or left unstimulated. Flow cytometry was used to determine 
percentages of A) IFN-γ and B) TNF produced by CD4 T cells at 7dpi. Error bars denote mean ± 
SEM and analysed using the unpaired student t-test with/without Welch’s correction, (**p<0.01). 
 
CysLTR1 deficiency had no effect on spleen cytokine and chemokine profile after LM 
infection: We determined spleen cytokine responses in the tissue homogenates. Nitric 
oxide production was unaffected at both 3- and 7-dpi (Figure 20A). We measured pro-
inflammatory cytokines by ELISA, and there was a significant increase in IL-1α at 3dpi in 
the KO compared to WT (Figure 20B). At both 3dpi and 7dpi, IL-17, IL-12p70, and IL-23 
secretion were undetectable (data not shown). The other pro-inflammatory cytokines, 
however, were comparable in KO and WT at both time points. In addition, there were no 
significant differences in the production of TGF-β and IL-10 secretion in both KO and WT 
mice (Figure 20H and 20I), however, a significant decrease in IL-4 secretion at 7dpi in KO 
homogenates (Figure 20J). We then measured chemokine (CXCL2, CCL5, CCL3, CXCL1, 
CXCL5, and CXCL2) and growth factor (GM-CSF) secretion by KO and WT mice in 
spleen homogenates, and there were no significant differences in all measured chemokines 
and growth factors (Figure 21A-21G). Altogether, this suggests that the spleen 




Figure 20: Nitric oxide, pro-inflammatory, regulatory and Th2 cytokine production in 
CysLTR1 knockout spleen homogenates post-L. monocytogenes infection. CysLTR1 deficient 
mice and their littermate controls were infected with 1.1x105 LM CFUs/200µL per mouse 
intraperitoneally and the mice were sacrificed at 3 and 7dpi (n = 6 per group). The spleen was 
collected for homogenates and measured A) nitric oxide, pro-inflammatory; B) IL-1α, C) IL-1β, 
D) IFN-β, E) IFN-γ, F) IL-6,  and G) IL-12p40, regulatory; H) TGF-β, _I) IL-10 and Th2 cytokines 
J) IL-4 by ELISA. Data is representative of two experiments. Error bars denote mean ± SEM and 







Figure 21: Chemokine and growth factor production in CysLTR1 knockout spleen 
homogenates post L. monocytogenes infection. CysLTR1 deficient mice and their littermate 
controls were infected with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice 
were sacrificed at 3- and 7-dpi (n = 6 per group). The spleen was collected for homogenates and 
measured A) CXCL2, B) CCL5/RANTES, C) CCL3, D) CXCL1, E) CXCL5, F) CCL2 and G) 
GM-CSF by ELISA. Data is representative of two to three experiments. Error bars denote mean ± 
SEM and analysed using the unpaired student t-test with/without Welch’s correction. 
 
CysLTR1 deficient splenocytes have increased IFN-γ production upon re-stimulation 
ex vivo: Following total cytokine concentrations measurement in the spleen, we also 
stimulated splenocytes with anti-CD3 antibody, heat-killed LM (HKLM) or left them 
untreated and measured cytokine secretion potential of T cells. Treating cells with HKLM 
was done to determine the antigen-specific T cells responses. At 3dpi, there were no 
differences in IFN-γ secretion (Figure 22A), while there was a significant increase in IFN-
γ production by KO splenocytes post-HKLM re-stimulation (Figure 22B). IL-2 secretion 
from stimulated splenocytes was similar at 3dpi (Figure 22C), whereas HKLM stimulation 
of KO splenocytes resulted in a significant reduction at 7dpi (Figure 22D). However, IL-4, 
IL-17, IL-10 and TGF-β secretion by splenocytes was comparable between the KO and 
WT cells both at 3- and 7-days post-LM infection (Figure 22E-22L). Decreased IL-2 
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secretion is actually in line with decreased T cell numbers in the spleen at 7dpi which can 
explain decreased maintenance of these cells.  
 
Figure 22: Re-stimulation of KO splenocytes with heat-killed LM increased IFN-γ production 
seven days post-infection. CysLTR1 deficient mice and their littermate controls were infected 
with 1.1x105 LM CFUs/200µL per mouse intraperitoneally and the mice were sacrificed at 3- and 
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7-dpi (n = 6 per group). Splenocytes were stimulated for cytokine production using anti-CD3, heat-
killed LM (HKLM) or left unstimulated for 3 days at 37oC. A-B) IFN-γ, C-D) IL-2, E-F) IL-4, G-
H) IL-17, I-J) IL-10 and K-L) TGF-β levels were measured in supernatants by ELISA. Data is 
representative of two experiments. Error bars denote mean ± SEM and analysed using the unpaired, 
student t-test with/without Welch’s correction, (*p<0.05). 
 
CysLTR1 deficiency had no effect on systemic cytokine secretion after LM infection:  
We then measured systemic cytokines at 3 and 7 days in serum by ELISA post-LM 
infection. There were no significant differences in cytokine levels measured at both time 
points (Figure 23A and 23B). At 3dpi, there was an increasing trend in IFN-γ, IL-17 
secretion in KO compared to the WT controls. This increasing trend was reversed in all 
cytokines measured at 7dpi. This suggests that as in the spleen, serum cytokine levels do 
not differ significantly; however, we observed some differences in cytokine/chemokine 
levels in the liver, again highlighting tissue-specific effects of CysLT signalling.  
 
 
Figure 23: CysLTR1 deletion has no effect on serum cytokines during L. monocytogenes 
infection in mice. CysLTR1 deficient mice and their littermate controls were infected with 1.1x105 
LM CFUs/200µL per mouse intraperitoneally and the mice were sacrificed at 3- and 7-dpi (n = 6 
per group). The cardiac puncture was performed to collect blood for cytokine levels in response to 
LM infection. A-B) Measured cytokine (IFN-ƴ, IL-17, IL-12p40, IL-6, and IL-10) secretion in the 
blood by ELISA 3- and 7-dpi. Data is representative of two experiments.  Error bars denote mean 
± SEM and analysed using the unpaired student t-test with/without Welch’s correction.  
 
3.6. Survival benefit in CysLTR1 deficient mice is dependent on genetic background 
of animals during L. monocytogenes infection.  
We were able to show that CysLTR1 is highly expressed in the mice liver and spleen during 
LM infection, and KO mice have Moreover, sub-lethal dose of LM infection to evaluate 
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the role of CysLTR1 as a function of time revealed no major differences in bacterial loads, 
however, increased neutrophilic recruitment and reduced lymphoid cells in the spleen. We 
then evaluated the effect of CysLTR1 deletion has on the survival of mice during LM 
infection by using LD50 dose. We infected C57BL/6 CysLTR1 KO mice and their littermate 
controls with about 1x106 LM CFUs/200µL intraperitoneally and monitored over a period 
of 15 days. CysLTR1 KO mice showed a modest increase in susceptibility, however, not 
significant to the LM infection when compared to littermate controls (Figure 24A). 
Consistent with our other data with BALB/C mice, we also performed mortality experiment 
with BALB/C CysLTR1 KO mice. Remarkably, we found that deletion of CysLTR1 in 
BALB/C mice displayed susceptibility during LM infection (Figure 24B). We speculate 
this could be due to the increased neutrophilic recruitment and tissue pathology caused by 
neutrophilia and likely predisposed susceptibility of BALB/C background. 
 
 
Figure 24: Effect of CysLTR1 deletion on mice survival during L. monocytogenes infection. 
C57BL/6 CysLTR1+/+ and CysLTR1-/- mice (n= 9-10 mice per group) were infected with 1x106 
CFUs LM per 200µL and monitored for survival over 15 days (two pooled experiments). And 
BALB/c CysLTR1+/+ and CysLTR1-/- mice (n= 9-11 mice/group) were infected with 3.8x105 CFUs 
LM per 200µL and monitored for survival over 14 days. A) C57BL/6 and B) BALB/c mice survival 
curve post infection with LM. Statistically analysed by log-rank (Mantel-Cox) test, (*p<0.05).  
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CHAPTER 4: DISCUSSION 
4.1. CysLT receptors and Ltc4s expression in response to LM infection 
Cysteinyl leukotrienes have been well studied in asthmatic and allergic responses, with 
mostly pathophysiological functions of CysLTs in asthma being regulated through 
CysLTR1. And as a result, several antagonists (montelukast, pranlukast, and zafirlukast) 
for CysLTR1 have been developed and are being used in clinical practice (108).  CysLTR1 
and CysLTR2 induce similar signalling events, which include calcium (Ca2+) influx and 
inositol phosphate accumulation in the cells (159–161). However, they mediate different 
responses in vivo and have different cellular and tissue distribution (162–164). CysLTR1 
has been shown to be mainly expressed in the peripheral blood leukocytes, including 
eosinophils, monocytes, neutrophils, basophils, DCs, B cells, T cells, mast cells, interstitial 
lung macrophages and bronchial smooth muscle cells, and in the lung, spleen, pancreas, 
small intestines and other tissues (90, 162, 163, 165, 166). CysLTR2, on the other hand, 
has been shown to be highly expressed in tissues, such as the heart, adrenal tissue, lung, 
spleen, endothelium tissue, and in the peripheral blood leukocytes (163). Even though these 
receptors are widely expressed in different cells and tissues, it is unknown whether their 
expression can be induced by a bacterial infection and their potential role during bacterial 
infection. We showed that LM infection induce both CysLTR1 and CysLTR2 expression 
together with LTC4S expression both in vivo and in vitro. In vivo, the expression of these 
receptors and LTC4S are highly upregulated at a later stage of infection, while at 
macrophage level CysLTR1 and LTC4S are upregulated early after infection. Interestingly, 
macrophages stimulated with HKLM, showed CysLTR1, CysLTR2 and LTC4S mRNA 
expression was unaffected, suggesting that live LM is required to induce their expression. 
CysLTs are calcium flux inducers, and calcium plays a crucial role in a variety of 
eukaryotic cellular signalling processes, which include exocytosis, contraction, 
metabolism, gene transcription, fertilization and proliferation, and regulates actin 
microfilament (167). It has been demonstrated that LM transiently induces calcium influx 
through the production of LLO. It is believed that LM induces extracellular Ca2+ 
mobilization by LLO, and activates the downstream Ca2+-dependent signalling which is 
required for cell invasion (168). This could, therefore, suggest that LM might manipulate 
the CysLT pathway for Ca2+ flux for an efficient cellular invasion.  
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4.2. Characterization of CysLTR1 deficient mice at naïve state 
CysLTR1 knockout mice were generated by Yoshihide Kanaoka’s group (137), but the 
comprehensive immunological characterization of the mice has not been reported. In order 
to understand the role of this receptor and its signalling during intracellular bacterial 
infection, its deletion at naïve state should have no significant effect on mice. We first 
confirmed deletion by genotyping the KO and WT mice and able to show a successful 
deletion of the Cysltr1 gene. The KO mice have a 333bp gene size because of the neomycin 
resistance gene insertion into the mutant allele, instead of the actual Cysltr1 gene size 
(284bp). We further validated CysLTR1 deletion on tissues by measuring its mRNA 
expression and additionally, its deletion had no effect on Cysltr2 and Ltc4s mRNA 
expression. The reason why CysLTR2 expression is not affected by Cysltr1 deletion in 
mice, even though they are 31% homologous (169), shows that there are no feedback 
mechanisms involved in the expressions of CysLT receptor genes. Cysltr2 gene is located 
on chromosome 13, position 13q14 in humans (170), while it is located in chromosome 14 
in mice (137). Cysltr1 is located on the X chromosomes both mice and humans, position 
Xq13-Xq21 in humans (108, 137, 171). LTC4S, the enzyme responsible for the synthesis 
of cysteinyl leukotrienes, is not affected by Cysltr1 deletion, therefore this receptor has no 
effect on the enzyme’s expression or regulation. Full characterization of CysLTR1 KO 
mice revealed that CysLTR1 deletion does not alter mice immunity or organ pathology at 
naïve state. It was interesting that lung, liver, and spleen B cells in both WT and KO mice 
were higher compared to other lymphoid populations. B cells are believed to play a pivotal 
role in immunity because of their ability to produce antibodies, however their role is 
dependent of environmental stimulations such as growth factors, cytokines and 
intercellular interactions (172). As mentioned above, CysLTR1 can be expressed by 
various cells and tissues including bronchial smooth muscle cells, phagocytic cells and B 
lymphocytes. In B cells, CysLTR1 is said to be upregulated post-stimulation with CD40L 
and these cells have increased responsiveness to LTD4 in terms of antibody production 
(173). However, at steady state, CysLTR1 does not influence B cell recruitment or 
development but might play a role in antibody production during immune responses. It has 
been demonstrated that hematopoietic progenitor cells can be stimulated by a variety of 
cytokines into mature blood cells which include B cells, basophils, monocytes to 
macrophages, neutrophils, eosinophils and T cells through specific receptors and CysLTR1 
is expressed on the surface of these immune cells at various stages of development (166). 
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This, therefore, suggests that CysLTR1 signalling may play a role in both lymphoid cell 
and myeloid cell generation and recruitment however, we show that at naïve state CysLTR1 
has no major effect on the generation of these populations. Suggesting, CysLTR1 
signalling is potentially involved in immune regulation in response to inflammatory ques 
and pathogenic infection. We measured cytokine secretion in organ homogenates and 
serum, and there were no significant differences between the KO and WT cytokine 
secretion at naïve state. Taken together, our results demonstrated that CysLTR1 deletion in 
mice has no effect on organ pathology and proportion of immune populations. This had a 
small effect on cytokine and antibody secretion at naïve state.  
4.3. Effect of CysLTR1 deletion in macrophages for the control of LM infection in 
vitro 
Macrophages are important innate immune cells and they also play a key role in the 
initiation of adaptive immunity. Activation of macrophages increases phagocytosis and 
killing properties, membrane receptor expression, and secretion of cytokines to induce an 
appropriate pro-inflammatory immune response (174, 175). During LM infection, IFN-γ 
potentiates peritoneal macrophages to prevent its escape to the cytosol, inhibiting its 
growth. Moreover, IFN-γ, LPS, IL-6, and anti-IL-10 stimulated bone marrow-derived 
macrophages also inhibit LM escape and cytoplasmic growth (176, 177). In this study, we 
demonstrated that macrophages deficient of CysLTR1 showed comparable control of LM 
infection to wildtype macrophages. Despite no differences in bacterial burden in KO and 
WT BMDMs from C57BL/6 and BALB/c background, they varied in their cytokine 
profiles. Nitric oxide production was comparable at insufficient levels in both backgrounds 
in KO and WT macrophages, which explains the inability of macrophages to control LM 
infection. NO is a toxic L-arginine radical synthesized by inducible nitric oxide synthase 
in activated macrophages. IFN-γ and LPS are known to be potent NO synthase inducers in 
macrophages (178). During in vitro infections with pathogens such as Leishmania major, 
Toxoplasma gondii and Mycobacterium bovis, NO exhibits antimicrobial properties (179–
181). It has also been shown that it may be an important molecule during LM killing by 
macrophages stimulated by IFN-γ (182), however, there are studies contradicting this. 
During LM infection increased expression of nitric oxide synthase 2 (NOS2) and 
production of NO has been related to increased LM cell-to-cell spread (183). It has also 
been proposed that NO delays macrophage phagosome maturation that contain the bacteria, 
slowing the macrophage killing effect (184). During early allergic reactions, CysLTs and 
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NO are one of the mediators released following antigen-antibody interactions (185). It has 
also been shown that during an allergic response, nasal obstruction induced by LTD4 is 
inhibited by pranlukast and Nω-nitro-L-arginine methyl ester (L-NAME), NO synthase 
inhibitor (186), suggesting that NO secretion by activated CysLTR1 might have an 
essential role allergic inflammation. The comparable NO secretion in C57BL/6 BMDMs 
was accompanied by an increasing trend in IL-10 secretion. In contrast, BALB/c KO 
BMDMs showed a decreasing trend in IL-10 secretion. IL-10 is an inhibitor of macrophage 
pro-inflammatory cytokines, reactive oxygen species (ROS) and reactive nitrogen 
intermediates (RNI) production (187, 188). It has been shown to decrease nitric oxide 
levels and iNOS expression in LPS stimulated macrophages (189). Moreover, one study 
has demonstrated that IL-10 inhibits cysLT-induced activation of monocytes and dendritic 
cells (190). Our results show that: 1) Bacterial burden between the KO and WT 
macrophages generated from both backgrounds is comparable, accompanied by similar 
production of NO, which explains bacterial survival within these cells. 2) Based on the 
available literature, there is a possibility that NO is insufficient for effective killing of LM, 
as it has been shown that both ROI and RNI play a role in entrapping LM within the 
phagosome. Therefore, even though there is evidence that NO promotes the cell-to-cell 
spread of LM, activated macrophages have been shown to retain the bacterium within the 
phagosome through localization of RNI or ROI to the vacuole (46). 3) We have shown that 
LM infection induces expression of CysLT receptors and their enzyme. Even though 
CysLTR1 activation induces NO secretion in Th2 settings of allergic responses, activation 
of this receptor in Th1 settings with different environmental cues might have a different 
role. Here, we demonstrate that NO secretion was not affected in CysLTR1 knockout 
macrophages in LM infection. 4) The differences we observed in cytokine profiles between 
the two backgrounds suggest that macrophages generated from C57BL/6 are slightly 
different from BALB/c mice which have different immune regulation patterns. For 
instance, C57BL/6 KO macrophages have an increasing trend in IL-10 secretion, which 
inhibits pro-inflammatory cytokine secretion required for effective killing of LM. This 
increased IL-10 production resulted in a decreasing trend in TNF secretion is which 
required for effective killing of LM, and MIP2, which has been shown to provide resistance 
to LM infection (191). However, in BALB/c KO macrophages, the anti-inflammatory IL-
10 secretion has a decreasing trend which is accompanied by decreasing trend in IL-6, TNF 
and MIP2, also validating their inability to kill LM. Most studies, however, have reported 
that for an effective secretion of pro-inflammatory cytokines and effective LM killing by 
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macrophages, macrophages must be pre-conditioned by either IFN-γ or LPS. Therefore, 
further in vitro experiments are required to assess LM growth in IFN-γ/LPS-stimulated 
macrophages.  
4.4. Effect of CysLTR1 deletion during LM infection in mice  
Neutrophils play the first line of defence during LM infection by direct killing of infected 
cells or the bacterium itself, however, there are conflicting reports on the role of neutrophils 
during the control of LM infection. Neutrophils in the liver have been demonstrated to kill 
bacteria from apoptotic hepatocytes or by directly lysing infected hepatocytes (192, 193). 
They are also known to secrete chemokines that recruit more immune cells to the site of 
infection (194). However, Shi et al., 2011, demonstrated that mice depleted of neutrophils 
are less susceptible to LM infection than those depleted of monocytes, suggesting that 
neutrophils are dispensable during LM infection (195). Our study further adds that, even a 
significant increase in neutrophils in CysLTR1 KO mice at 3 and 7 dpi, had no differences 
in organ bacterial burdens. This, therefore, validates that neutrophils may have no to 
minimal effect on bacterial killing, and potentially play a role in the spread of the bacterium 
and tissue pathology instead.  
More recently, neutrophils were shown to regulate macrophage inflammatory signalling by 
inducing a rapid and sustained suppression of NF-κB activation (196). Interestingly, at 7dpi 
in the liver of KO mice, there was a significant increase in monocyte-derived macrophages, 
while neutrophils percentages were comparable between the KO and WT at this time-point. 
This suggests that increased neutrophils might be inhibiting the recruitment of these 
macrophages, hence the inability to control bacterial burden, as these cells have been 
shown to be unable to kill LM infection (197). It has been reported that CysLT receptor 
expression in neutrophils is lesser compared to other cells, but upon 5-LOX activation 
neutrophils are able to secrete LTA4 to cells that can synthesize LTB4 and CysLTs. LTB4 
activates neutrophils causing the release of proteases, myeloperoxidases and reactive 
oxygen species, which can cause tissue destruction (198). However, when neutrophils are 
stimulated with LTC4 and LTD4, they have moderate activation of Ca2+ mobilization and 
nitric oxide production when compared to LTB4 stimulation (199). Deletion of CysLTR1 
has no effect on leukotriene (LT) and cysteinyl leukotrienes (CysLTs) synthesis, however, 
it surely affects CysLT activities or signalling. Here, we demonstrated that the deletion of 
CysLTR1 promoted neutrophil recruitment during LM infection. The increase in the 
recruitment of neutrophils in CysLTR1 deficient mice during LM infection could be due to 
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LTB4 action, though, further investigation is required. However; increased frequencies and 
possible augmented activation of neutrophils can also explain the increased tissue 
destruction in KO mice spleen.  
We also demonstrated that at early LM infection, liver and spleen lymphoid cells were 
significantly reduced in KO mice. In the liver, this reduction was significant in B cells, NK 
cells, and CD4 T cells, while in the spleen all the lymphoid cells, except for γδ T cells, 
were significantly reduced. The lymphoid cells are important for adaptive immunity 
against LM infection. During LM infection, B cells are said to be susceptible to the infection 
(200) and are killed through apoptosis depending on the infection dose of LM (201, 202). 
During innate immunity to LM infection, NK cells are said to produce IFN-γ which is 
required to increase myeloid cell antimicrobial activities against invading intracellular 
bacteria (36, 37). Therefore, NK cells induce host immunity to bacterial infections. 
However, Clark et al., 2016, demonstrated that activated NK cells increase host 
susceptibility to LM infection which is independent of their IFN-γ production. They 
correlated the increased susceptibility to LM infection with enhanced production of IL-10 
by NK cells, which was promoted by the LM virulence factor p60 (38).  CD4 T cells also 
participate in host protection during LM infection, they differentiate into Th1 cells inducing 
the production of Th1-derived cytokines, such as IFN-γ (203–205). CD8 T cells induces 
immunity to LM by either lysing the infected cells by direct exposure of intracellular 
bacteria to perforin and granzymes, or by secreting IFN-γ that in turn activates 
macrophages for effective killing of the bacteria (55). As aforementioned, CysLTs are 
potent inducers of Ca2+ influx and it has been demonstrated that when LTD4 binds to 
CysLTR1 there is an induction of Ca2+ fluxes, which result in chemotaxis of αβ and γδ T 
cells to the inflamed tissue (206). Therefore, deletion of CysLTR1 could be reducing Ca2+ 
influx and recruitment of lymphocytes to the site of infection, hence reduction in the 
lymphoid cell population in the liver and spleen of KO mice during LM infection. During 
inflammatory responses like in rhinosinusitis allergic reaction, leukocytes that express 
CD45 on their cell surfaces, which include T cells, B cell and monocytes, CysLTs play a 
role in their activation and recruitment. It has been demonstrated that CysLTR1 expression 
in these cells is highly upregulated during allergic inflammation and suggested that 
CysLTR1-expressing cells maybe selectively recruited to the site of inflammation or may 
replicate and survive through the influence of CysLTs (207). Therefore, increased 
lymphoid cells in the liver and spleen of WT mice during LM infection could be due to 
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increased CysLTR1 expression in response to the infection and its interaction with its 
binding ligands which result in recruitment of lymphoid cells to the site of infection. Even 
though the increased recruitment of CD4 T cells in the liver of WT mice; in terms of 
activation, proliferation and IFN-γ production, they are comparable to those of KO mice. 
This further explains the comparable bacterial control observed between the KO and WT 
mice. Interestingly, though CD8 T cells between the two groups were similar but KO mice 
had slightly increased CD8 effector/effector memory T cells, decreased IFN-γ production, 
and increased perforin and granzyme B secretion. However, the granzyme B and perforin 
secretion were not efficient enough to kill the bacteria on their own as, IFN-γ production 
by T cells is required for activation of macrophages and subsequent secretion of granzyme 
B and perforin (58). Despite increased granzyme B and perforins, KO mice had 
significantly increased CD8 KLRG1+ PD1+ T cells, indicating these cells are exhausted 
and therefore not able to contain bacterial growth. Nevertheless, this validates that 
CysLTR1 and its ligands might play a role in terminal differentiation of lymphocytes 
during inflammatory responses. It is possible that during secondary infection with LM these 
cells will be able to mount a protective immune response. In the spleen of KO mice, we 
observed a decrease in CD4 naïve T cells, increased CD4 central memory, effector/effector 
memory T cells, and KLRG1+ PD1+ T cells. This demonstrates that, even though there was 
a significant reduction in CD4 T cells, LM infection still results in their activation and 
CysLTR1 deletion might be affecting their survival and effector phenotypes. This also 
affected the production of IFN-γ by KO CD4 T cells, and perforin by KO CD8 T cells, 
subsequently their ability to clear LM infection. CD8 T cells of KO mice, however, had a 
significant reduction of naïve and central memory cells, increased effector/effector 
memory T cells and proliferation. Despite reduced in percentages, they were active and 
proliferating but were not effective at clearing the bacteria. Moreover, these cells are unable 
to produce sufficient IFN-γ, perforin and granzyme B which may be a result of exhaustion 
(KLRG1+ PD1+ phenotype).  
In liver, we showed a significant reduction in IFN-γ, IL-17 and IL-12p70, and a decreasing 
trend of IFN-β. All these cytokines are required for the effective clearance of LM infection 
and their reduction further validates the inability of CysLTR1 deficient mice to control LM 
infection. Chemokines play a crucial role during immune defence because of their ability 
to attract immune cells to the site of infection or inflamed tissue (208). CysLTR1 KO mice 
has significantly reduced production of CXCL2, CXCL10 and growth factor, GM-CSF 
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early after infection. CXCL2 is secreted by mast cells and macrophages as a 
chemoattractant for early recruitment of neutrophils (209). CXCL10 has been associated 
with a variety of diseases as it is involved in chemotaxis, apoptosis, cellular growth and 
angiogenesis (210). CXCL10 receptor, CXCR3, is predominantly expressed in T cells, NK 
cells, dendritic cells, macrophages and B cells therefore, CXCL10 plays a role in 
recruitment of these cells (210–212). The reduction in production of CXCL10 in the liver 
correlates with the reduction of lymphoid cells in these KO mice. This therefore suggests 
that CysLTR1 deletion might be affecting the ability of macrophages and monocytes to 
secrete this chemokine to attract lymphoid cells to the site of infection. The reduced IFN-
γ production also influenced the reduction of CXCL10, because it has been shown that 
leukocytes produce of CXCL10 in response to IFN-γ (213).  The inability of CysLTR1 KO 
mice to recruit lymphoid cells to the site of infection is due to reduced pro-inflammatory 
cytokine production and chemokine secretion required for chemotaxis of lymphoid cells. 
However, we aim to investigate further the reason why mice have increased neutrophil 
recruitment while at the same time decreased lymphocyte chemotaxis with an increased 
exhausted phenotype. 
4.5. Effect of CysLTR1 deletion on mice survival during LM infection 
Lastly, we conducted mortality studies to determine the effect of CysLTR1 deletion on 
mice survival. This revealed that the KO mice appeared to be more susceptible to LM 
infection than their littermate controls. Our time-course experiments partially validate the 
susceptible phenotype observed in survival studies. For instance, KO mice have increased 
neutrophils which could cause tissue destruction, reduced recruitment of T cells and 
decreased pro-inflammatory cytokines thereby hampering the optimal adaptive immune 
responses. Moreover, a mortality study for CysLTR1 KO mice on BALB/c background, 
showed that CysLTR1-deficient mice were indeed susceptible to LM infection. These 
results suggest that intact CysTLR1 signalling contribute to host protection against 
listeriosis. Further studies will focus on the analysis of tissue pathology and systemic 
cytokine responses in mice. 
4.6. Conclusion and future studies 
In this study, we demonstrated for the first time that LM infection induces expression of 
CysLTR1, CysLTR2, and LTC4S both in vivo and in vitro. We also demonstrated that the 
deletion of CysLTR1 has no effect on homeostasis in mice. CysLTR1 deletion had no effect 
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on LM growth in macrophages, with differential cytokine responses from both C57BL/6 
and BALB/c background. However, we intend to conduct more studies to investigate the 
effect of CysLTR1 signalling at the cellular level when these macrophages are pre-treated 
with IFN-γ or other stimulants (LPS, TNF and PGE2) before LM infection which can better 
mimic macrophage responses in vivo. We suspect that there will be differences in the ability 
of WT and KO macrophages to control LM infection and in their cytokine and nitric oxide 
production. We also reported that CysLTR1 deletion in vivo has no effect on bacterial 
control, however, KO mice had increased neutrophils and reduced lymphoid cells. As 
mentioned before, CysLTs play a role in the recruitment of lymphocytes to the site of 
infection or inflamed tissue (206), we, therefore, suggest that deletion of CysLTR1 might 
have affected the attraction of these lymphoid cells and also the secretion of chemokines 
required for activation and recruitment of inflammatory cells. In conclusion, CysLTR1 
signalling plays a role in lymphoid cell activation and recruitment during early immune 
responses to LM infection and regulates the recruitment of neutrophils. 
Further studies: WE will activate of KO and WT macrophages with IFN-γ and/or LPS to 
demonstrate whether the inability of CysLTR1 deficient macrophages to control LM 
infection is due to its deletion and in turn insufficient inactivation on macrophages. We 
also will infect WT macrophage with mutant LM strains that lack the expression of the 
virulence factors, such as LLO or ActA, to determine which virulence factor is required for 
the upregulation of CysLT receptors and LTC4S expression. Since we observed a stronger 
phenotype on BALB/c mice during mortality studies, we plan on conducting time course 
studies in this background to further understand the immune mechanisms. Furthermore, we 
will perform secondary infections on C57BL/6 mice, which will give us a better 
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Figure S1: Gating strategy to identify thymus T cells. From the time gate, we gated for single 
cells, then singlets, then we removed the debris. We then gated for live cells from SSC-A and 
live/dead. From the live cells we gated for the CD4+ CD8-, CD4+ CD8+, CD4- CD8+ and CD4- CD8- 




Figure S2: Lung, liver and spleen gating strategy for lymphoid cell populations. From the time 
gate, we gated for single cells, to singlets, then gated out the debris, then gated for live cells from 
SSC-A and live/dead. From the live cells, we gated for γδ T cells (γδTCR+ CD3+) using γδTCR and 
CD3 markers. From the rest of the cells, gated for NK cells (CD3- NK1.1+). From NK1.1- cells we 
gated for CD3 T cells (CD3+ CD19-) and B cells (CD3- CD19+). From CD3+ cells we gated for CD4 
T cells (CD4+ CD8-) and CD8 T cells (CD4- CD8-).  From both CD4+ and CD8+ T cells we gated 
for follicular T helper cells (CXCR5+ PD1+), parenchymal/vascular and exhausted/terminally 
differentiated cells using KLRG1 and PD1, naïve T cells (Q5: CD62L+ CD44-), central memory T 
cells (Q6: CD62L+ CD44+) and effector/effector memory T cells (Q7: CD62L- CD44+). The 





Figure S3: Lung myeloid cell populations gating strategy. From the time gate, we gated for 
single cells, to singlets, then gated out the debris (not shown), then gated for live cells from SSC-
A and live/dead. From the live cells, we gated for neutrophils (Ly6G+ CD11b+). From the negative 
population we gated for CD64+ cells and CD64- cells. From the CD64- cells we gated for 
eosinophils (CD11b+ SiglecF+). From the negative population, we gated for DCs (CD11c+ 
MHCII+). From DCs we gated for cDC1 (CD103+ CD11b-) and cDC2 (CD103- CD11b+). And from 
the CD64+ cells we gated for monocyte derived DCs (MoDC, CD11b+ CD11+). From the negative 
cells we gated for alveolar macrophages (CD11c+ SiglecF+) and from the negative population we 
gated for interstitial macrophages (SSC-A CD11b+) using SSC-A and CD11b. The analysis was 





Figure S4: Liver myeloid cell populations gating strategy. From the time gate, we gated for 
single cells, to singlets, then gated out the debris, then gated for live cells from SSC-A and 
live/dead. From the live cells, we gated for neutrophils (Ly6G+ CD11b+). From the neutrophil 
negative population, we gated for eosinophils (CD11b+ SiglecF+). From the eosinophil negative 
population, we gated for monocytes (Ly6C+/Gr1+ CD11b+). From the monocyte negative 
population, we gated for Kupffer cells (CD11bmid F4/80+). From the negative population, we gated 
for DCs (CD11c+ MCHII+). From the DCs, we gated for cDC1 (CD103+ CD11b-) and cDC2 
(CD103- CD11b+). From the CD11c+MHCII+ subset, we gated for monocyte derived macrophages 





Figure S5: Spleen myeloid cell populations gating strategy. From the time gate, we gated for 
single cells, to singlets, then gated out the debris (not shown), then gated for live cells from SSC-
A and live/dead. From the live cells, we gated for neutrophils (Ly6G+ CD11b+). From the negative 
population, we gated for CD11b positive and CD11c positive cells. From the CD11b positive cells 
we gated for MHCII SSC-A subset, from which we gated for cDC1 (CD11b+ CD8-) and cDC2 
(CD11b- CD8+). From CD11c positive cells, we gated for monocytes () and from the negative 
population, we gated for marginal zone macrophages (CD11b+ F4/80low) and red pulp macrophages 






Figure S6: Liver and spleen T cell intracellular staining gating strategy. From the time gate, 
we gated for single cells, then singlets, then we removed the debris. We then gated for live cells 
from SSC-A and live/dead. From the live cell gating, we gated for the CD4 and CD8 T cells. From 
CD4 T cells we gated for CD4 T cell cytokines, TNF (CD4+ TNF+), IFNy (CD4+ IFNy+) and 
proliferating CD4 T cells (CD4+ Ki67+). From CD8+ cells we gated for cytokines, granzyme B 
(CD8+ granzyme B+), perforin (CD8+ perforin+), IFNy (CD8+ IFNy+), and proliferating CD8 T 






Figure S7: Lung, liver and spleen CD4 and CD8 T cell exhaustion markers at naïve state. 
CysLTR1 deficient mice and their littermate controls were sacrificed. A-B) Lung, C-D) liver and 
E-F) spleen single cells were stained for CD4 and CD8 T cell exhaustion markers, PD1 and 
KLRG1. Data is representative of three independent experiments.  Error bars denote mean ± SEM 






Figure S8: Liver CD4 and CD8 T cell exhaustion and homing markers post-L. monocytogenes 
infection. CysLTR1 deficient mice and their littermate controls were infected with about 1.1x105 
LM CFUs/200µL per mouse intraperitoneally and sacrificed the mice at 3- and 7-dpi (n = 6 per 
group). A-D) Liver single cells were stained for CD4 and CD8 T cell exhaustion and homing 
markers, PD1 and KLRG1 at 3- and 7-dpi. Data is representative of two independent experiments.  
Error bars denote mean ± SEM and were statistically analysed using the unpaired student T-test 






Figure S9: Spleen CD4 and CD8 T cell exhaustion markers post-L. monocytogenes infection. 
CysLTR1 deficient mice and their littermate controls were infected with about 1.1x105 LM 
CFUs/200µL per mouse intraperitoneally and sacrificed the mice at 3- and 7-dpi (n = 6 per group). 
A-D) Liver single cells were stained for CD4 and CD8 T cell exhaustion markers, PD1 and KLRG1 
at 3- and 7-dpi. Data is representative of two independent experiments.  Error bars denote mean ± 
SEM and were statistically analysed using the unpaired student T-test with/without Welch’s 
correction, (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
 
 
 
 
 
